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ABSTRACT 
Alcohol abuse during pregnancy has been associated with Fetal Alcohol 
Spectrum Disorder (FASD). Research to date has focused on the role played by 
ethanol in the development of this disorder. In addition to ethanol, alcoholic 
drinks also contain methanol. Hence, consumption of alcohol can also lead to 
methanol accumulation. Methanol is metabolized to formaldehyde, which is then 
rapidly metabolized to formate, a toxic metabolite. Folate, a B-vitamin and 
antoxidant, is a cofactor in the metabolism of formate. This study assessed the 
relationship between formate and folate, formate kinetics in folate deficiency and, 
changes in antioxidant capacity during formate insult in folate deficiency. The 
findings of this study would lead to a better understanding of the role of formate 
in the development of the etiology of FASD and form the basis of future 
research.  
The relationship between formate and folate was investigated in 
intoxicated human female subjects, sober drug rehabilitating females and, 
pregnant women. A negative (inverse) relationship was observed between plasma 
formate and folate in pregnant sober women (correlation coefficient = -0.4989). 
Such a relationship, however, was not observed in whole blood in alcohol 
intoxicated (correlation coefficient = 0.0899) and detox women (correlation 
coefficient = 0.2382). Because of the health promoting ingredients in grain and 
fruit based alcoholic drinks, antioxidant B-vitamins were higher during 
intoxication while homocysteine levels were lower. 
Formate kinetics during folate deficiency and changes in the body 
antioxidant capacity was investigated in folate deficient young swine. Folate 
deficiency altered formate kinetics leading to decreased systemic clearance (by 
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approximately 2.3 fold), increased half-life (by 2.5 fold) and, consequently 
increased exposure (by 2.7 fold). Folate deficiency alone compromised 
antioxidant capacity. However, the combination of folate deficiency and formate 
insult further compromised antioxidant capacity. 
In conclusion, methanol accumulates after alcohol intoxication, which 
can lead to formate build up in the body. During folate deficiency formate 
kinetics is altered leading to reduced formate clearance and increased exposure. 
Exposure to formate coupled to folate deficiency compromises antioxidant 
capacity, which can have deleterious effects on the fetus. 
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PREFACE 
This thesis describes the effects of folate deficiency on formate kinetics during 
intoxication and its relationship to antioxidant capacity in folate deficient young swine 
and human females as well as the methodologies used. Currently, two chapters have been 
published (Chapters 2 and 3), two have been submitted for publication in scientific 
journals (Chapter 5 and 6) and, two others (Chapters 1 and 4) are in the process of 
submission.  
Chapter 1 reviews background information, hypotheses, and objectives. Chapters 2 
and 3 describe the development of methods of analysis of formate and folate catabolites 
p-aminobenzoylglutamate and ap-acetamidobenzoylglutamate for use in formate levels 
and folate utilization, respectively. Chapter 4 describes methanol and formate levels in 
alcohol intoxicated females, sober drug rehabilitating females and, preganant women 
(formate levels only). It also describes the relationship between formate and folate in 
these subjects as well as homocysteine (Hcy) and B-vitamin (B6 and B12) status. 
Chapters 5 and 6 describe the kinetics of formate and folate utilization during formate 
insult in young swine, respectively. Chapter 7 discusses the results of entire thesis study 
and the conclusions derived therein. 
 
 
CHAPTER 1 
Introduction 
1.1 Alcohol Consumption and Abuse 
The World Health Organization (WHO) estimates that there are about 2 billion 
people worldwide who consume alcoholic beverages and 76.3 million with diagnosable 
alcohol use disorders (World Health Organization, 2004). The 1998-99 National 
Population Health Survey (Statistics Canada, 2002) found that 78% of Canadians 15 years 
and older had consumed alcohol in the past year, 12.6% were former drinkers, and 9.5% 
were abstainers. Since the 1980s rates of past-year use had generally declined. Men, 
younger people and those with higher incomes and education had the highest rates of 
drinking. Rates of alcohol use also varied among the provinces, from a low of 59% in 
Newfoundland and Labrador to a high of 78% in Alberta. The 2000-01 Canadian 
Community Health Survey (Statistics Canada, 2003) reports a significant gender 
difference in the prevalence of heavy drinking (i.e., drinking 5 or more drinks per 
occasion 12 or more times in the past year), with 29.0% of current male drinkers 15 years 
and over, and only 11.4% of their female counterparts drinking to this extent. The rates 
of past-year use among high school students in Canada ranged from 48% to 65%, with 
rates increasing considerably with age (e.g., 80% in grade 12 in Ontario). There is 
evidence that rates of binge drinking have increased among high school and university 
students through the past decade. It was estimated that 4% of Canadians were alcohol-
1 
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dependent in 1994. Among Canadians 16 years and older who were current drinkers, 
10% (about 1.5 million Canadians) had driven a vehicle after consuming "too much 
alcohol" by their own account. 
Alcohol consumption during pregnancy has been associated with a variety of 
disorders in the developing fetus. These disorders consist of a wide spectrum of effects 
ranging from mild to extreme manifestations known as Fetal Alcohol Spectrum Disorder 
(FASD). Smith and Jones (Jones & Smith, 1973) first described the distinct dysmorphic 
condition associated with maternal alcohol abuse during pregnancy now known as 
FASD. Fetal alcohol spectrum disorder consists of a pattern of anomalies occurring in 
the babies born to drinking women and consists of (a) pre- and/or postnatal growth 
retardation, (b) morphological anomalies, and (c) central nervous system (CNS) 
dysfunction (1998b; Hannigan et. al., 1992; Rosett, 1980; Streissguth, 1986; Hannigan et. 
al., 1992).  
1.1.1 Types of Alcoholic Beverages and Their Various Alcohol Contents 
The alcoholic beverage market includes the three traditional forms of alcoholic 
beverages – beer, wine, and distilled spirits as well as a more recent fourth category called 
flavored alcoholic beverages (FABs), which is a cross between alcohol, fruit juices, 
flavorings, and soft drinks that the alcohol industry has given a variety of labels: ‘‘low 
alcohol coolers’’, ‘‘flavored alcoholic beverages’’, ‘‘flavored malt beverages’’, ‘‘alcopops’’, 
‘‘malternatives’’, ‘‘ready-to-drink beverages’’, and ‘‘low alcohol refreshers’’. Non-distilled 
beverages (wines and beers) have a maximum alcohol concentration of about 14 % by 
volume while distilled beverages (liquors and whiskeys) can have a maximum alcohol 
  3
concentration of 100%, though most are in the 40-50% range. Therefore, one glass of 
beer (12 oz beer; 4.5% alcohol) is equivalent to one glass of wine (4.5 oz glass of wine; 
12% alcohol), which is similar to one mixed drink (1.5 oz mixed drink with 40% alcohol). 
In Canada, a standard drink of alcohol (ethyl alcohol or ethanol) should contain 13.6 
grams or 17 ml of absolute alcohol-the amount contained in a 12-ounce (341ml) bottle of 
regular (5%) beer, five ounces (142 ml) of (12%) table wine or 1.5 ounces (43 ml) of 80-
proof liquor. Table 1.1 shows a summary of the types of alcohol in the markets and the 
various alcohol contents. However, actual mean ethanol content of alcoholic drinks in 
the market is much higher (approximately 11.7% translating to about 0.67 oz) (Kerr et. al., 
2005). For example, spirits contain 0.89 oz (48.3% larger than a std drink), wine = 0.66 
oz (10% larger), beer = 0.56 oz (6.7% less) and malt liquor = 7.23%v/v (Bluthenthal et. 
al., 2005; Logan et. al., 1999).In addition to ethanol, alcoholic beverages also contain 
methanol (Sprung et. al., 1988; Caldwell, 1986; Kapur & Maziar, 1993; Tintinalli, 1995). 
The methanol in such drinks is congeners, a by-product of fermentation and distillation. 
Congeners are present in distilled or fermented drinks (wine, scotch, brandy, rum, and, to 
a lesser extent, vodka and gin) and give liquor its unique taste and are often not removed 
for fear of altering the characteristic taste. It is, therefore, without doubt that 
consumption of such alcoholic beverages would result in significant blood levels of 
ethanol and methanol. Table 1.2 lists the methanol contents of various beverages and 
blood levels obtained.  
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Table 1.1: Types of alcoholic beverages and their alcohol contents.  
Beverage 
Alcohol content  
(Percentage by volume) 
Brandy 40 - 50 
Whisky 40 - 55 
Rum 40 - 55 
Wines (Port, Sherry Champagne, etc) 10 - 22 
Beer 4 - 8 
Flavored Alcoholic Beverages  5 - 8 
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Table 1.2: Methanol levels in various alcoholic drinks and blood following consumption 
of 1L of beverage.  
Beverage MeOH in beverage (mg/L) ∗ MeOH (mM) in blood∗∗
Beer 4-50 0.002-0.030  
White wine 15-45 0.009-0.027  
Red wine 70-130 0.042-0.078  
Cognac 180-370 0.10-0.22  
Calvados 310-640 0.18-0.38  
Kirsch 1900-2500 1.1-1.50  
Plum 3000-4500 1.80-2.70  
Slivovitz 1500-4000 0.907-2.40  
Liquor 10-560 0.006-0.33  
Rum 6-70 0.004-0.042  
Scotch whisky 100-130 0.06-0.078  
Irish whisky 10-110 0.006-0.066  
US whisky 200-330 0.120-0.199  
Cornwine 5-100 0.003-0.06  
Aquavit 5-650 0.003-0.391  
Gin 10-1350 0.006-0.812  
Vodka 5-170 0.003-0.102  
∗from Sprung et. al., 1988. ∗∗Maximum blood MeOH levels following consumption of 1 
litre of beverage in a 150 lb, 5’8’’, 25 years old male. 
 
1.1.2 Definition of Binge Drinking 
The national institute on alcohol abuse and alcoholism (NIAAA) (National 
Advisory Council on Alcohol Abuse and Alcoholism, 2004) defines binge drinking as “a 
pattern of drinking alcohol that brings blood alcohol concentration (BAC) to 0.08 gram 
percent or above”. For the typical adult, this pattern corresponds to consuming 5 or 
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more drinks for males, or 4 or more drinks for females in about 2 hours. A "drink" refers 
to half an ounce of alcohol (e.g., one 12–oz. beer, one 5–oz. glass of wine, or one1.5–oz. 
shot of distilled spirits). It is important to note that the number of drinks needed to reach 
a binge–level BAC is lower for some individuals such as older people or people taking 
other drugs or certain medications, than for the "typical adult." 
Therefore, binge describes an extended period of time (typically at least two days) 
during which time a person repeatedly becomes intoxicated. Binge drinking can result in 
acute intoxication, hangovers, headaches, nausea, shakiness and possible vomiting and 
memory loss. Other short-term risks of binge drinking include assaults, car accidents and 
risky behaviors such as swimming, driving, unsafe or unwanted sex, verbal or physical 
abuse. More important, binge drinking could pose significant risk to the fetus such as 
miscarriage and health effects (Figure 1.1) associated with elevated maternal ethanol and 
methanol levels such as FASD (Chaudhuri, 2000a; Day & Richardson, 1991; Zuba et. al., 
2002). 
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Figure 1.1: The harmful effects of alcohol consumption and folate deficiency. 
 
1.1.3 Prevalence of Alcohol Consumption 
Several studies have shown that alcohol consumption amongst women of 
childbearing age is high with 4% being considered alcohol dependent (Chambers et. al., 
2005; Center for Disease Control, 2004; Ebrahim et. al., 1998). In the study conducted by 
Cambers and coworkers (Chambers et. al., 2005), 43% of 100 pregnant low-income 
Latinas surveyed reported some alcohol use in the 3-months prior to pregnancy. Twenty 
percent (20%) reported at least one binge episode of 4 or more standard drinks during 
that time frame. Five percent (5%) reported drinking 7 or more drinks per week. In 
another study of women aged 18 - 44 years from the 2002 behavioral risk factor 
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surveillance system (BRFSS) survey, by the center for disease control (CDC) (CDC, 
2002), indicated that approximately 10% of pregnant women use alcohol, and 
approximately 2% engage in binge drinking or frequent use of alcohol. The results 
further show that more than half of women who do not use birth control (and therefore 
might become pregnant) report alcohol use with 12.4% reporting binge drinking.  
A study conducted by Ebrahim and coworkers found an increase in alcohol 
consumption in pregnant women in the U. S. from 9.5% in 1992 to 15.3% by 1995. They 
found that 14.6% of pregnant women consumed alcohol, and 2.1% consumed alcohol 
frequently (at least five drinks per occasion or at least seven drinks per week) (Ebrahim et. 
al., 1998). In another study (Ebrahim et. al., 1999) they found that pregnant women were 
one fifth (prevalence rate ratio 0.2, 95% confidence interval 0.1-0.2) likely to binge drink 
as would nonpregnant women. Pregnancy-related reduction in binge drinking was largest 
among women aged less than 30 years and among those who had quit smoking and 
smallest among black women. Binge drinking among pregnant women was independently 
associated with being unmarried, being employed, and smoking. Nonpregnant, 
unmarried, nonblack, college level education women aged 30 years or younger, who are 
employed, or a student, and currently smoking are more likely to binge drink (Ebrahim et. 
al., 1999). 
Consumption of high alcohol content drinks is also high among certain groups. 
For example, 88% of 329 African-Americans surveyed by Bluthenthal and co-workers 
(Bluthenthal et. al., 2005) preferred malt liquor beer (MLB) to regular beer. Four percent 
(4%) of daily or near-daily drinkers were MLB drinkers compared with 48% for regular 
beer (RB) and 29% for hard liquor (HL). Average alcohol consumption per occasion was 
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higher in MLB group (5.2 drinks, as compared with 4.2 for RB and 3.1 for HL), 
translating to daily average EtOH consumption of 6.97 oz, as compared with 2.13 oz for 
RB drinkers and 6.13 oz for HL drinkers. 
 
1.1.5 Social/Cultural Values and Alcohol Consumption 
Alcohol is one of the oldest social drinks known in many communities. A 
significant amount of alcohol consumption occurs in bars, taverns (accounting for 27% 
of total consumption among 20-24 year olds, compared to only 2% among those 65 and 
older) and social gatherings (accounting for 27% of drinkers aged 15-19 years) despite 
legal age restrictions. Friends are by far the dominant drinking companions for young 
people (Bobo & Husten, 2000). Several studies have shown alcohol consumption rates 
increase with age and that initiation and continued use is primarily influenced by 
sociocultural factors such as peer and family influences, demographics/socioeconomic 
status, advertising and, availability of alcohol itself (Bobo & Husten, 2000; O'Connor & 
Whaley, 2006; Pirkle & Richter, 2006).  
Alcohol use in adolescents is associated with drinking by parents, siblings and peers 
(Brook et. al., 1986; Rittenhouse & Miller, 1984; Scheier et. al., 1997; Williams et. al., 1998). 
Males are more likely to report current and binge drinking compared to females 
(Substance abuse and mental health services administration, SAMHSA, 1998) with a 
disproportionate number being from socioeconomically disadvantage background 
(D'Onofrio, 1997). Grube and co-workers (Grube & Wallack, 1994) observed that 
awareness of beer commercials among children in fifth and sixth grade was correlated 
with intentions to drink as adults.  
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1.1.6 Biochemistry and Clinical Toxicology of Alcohol Consumption 
1.1.6.1 Ethanol and Acetaldehyde 
Alcoholism is usually understood as an addiction to ethanol. Evidence suggests that 
it is the oxidation product of ethanol, acetaldehyde, which condenses with endogenous 
amines to form tetrahydroisoquinoline (TIQ) and - tetrahydro-beta-carboline (THBC) 
alkaloids which ultimately might be responsible for addiction (Brooks, 1997;Sprung et. al., 
1988). Commercial alcoholic beverages are made from natural products, and therefore 
contain, in addition to ethanol (EtOH), trace to small amounts of hundreds, if not 
thousands, of constituents and contaminates (also called congeners). While some 
congeners make up the distinctive characteristic of the beverage, others are by-products 
of the manufacturing process that are never removed for fear of altering the unique taste 
and smell of the drink. One of these congeners is methanol (MeOH) (see table 1.2). It is 
evident, without exception, that methanol is present in all alcoholic beverages. Its 
metabolite, formaldehyde, is a much more potent reaction partner for TIQ and THBC 
formation than acetaldehyde (Sprung et. al., 1988). It seems possible that methanol and its 
metabolites, formaldehyde and formate, play a more significant role in the 
pathophysiology and possibly the etiology of chronic alcoholism and FASD than ethanol. 
The specific pathophysiology of alcohol teratogenesis on the developing fetus is 
not known, but may involve free radical formation leading to oxidative stress and cellular 
damage. Acetaldehyde and formate, the metabolites of ethanol and methanol, 
respectively, have been implicated in DNA damage, and cellular death, as well as fetal 
malformations and death of the individual (Chaudhuri, 2000c; Chaudhuri, 2000b; Cook et. 
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al., 2001; Eriksson, 2001b; Hard et. al., 2001; Kitson, 1996; Riley et. al., 2001; Warren & 
Foudin, 2001). Excess alcohol consumption tends to result in compromised dietary 
habits and poor health maintenance behaviours. This may lead to maternal malnutrition, 
which in turn negatively affects fetal nutrition. Alcohol also decreases maternal intestinal 
absorption of nutrients, decreases placental uptake and availability of the nutrients to the 
fetus, and increases renal and hepatic metabolism of nutrients. Thus, it affects the 
metabolism of essential nutrients. 
Exposure of the fetus to acetaldehyde in the first trimester affects organogenesis 
and craniofacial development, leading to malformations due to excessive cell death in the 
midline of the developing embryo (Brooks, 1997; Chaudhuri, 2000c; Chaudhuri, 2000b; 
Eriksson, 2001a; Hard et. al., 2001; Kitson, 1996; Menegola et. al., 2001). Formate, a 
metabolite of methanol, is a much more potent toxic compound than acetaldehyde that 
has been implicated in cell death (Gonzalez-Quevedo et. al., 2002). 
 
1.6.3.1 Methanol and Formate 
Methanol is a hydrophilic, low molecular weight substance that freely diffuses, and 
therefore, is not concentrated in, or excluded from, any particular cell or body 
compartment. Methanol toxicity is an important public health concern because of the 
selective actions of formate on the retina, optic nerve and central nervous system (Eells 
et. al., 2000). The toxicity of methanol is mediated through formate. Thus, for methanol 
toxicity to occur, it must first be metabolized by alcohol dehydrogenase (ADH) to 
formaldehyde and thence to formate (Figure 1.2). Human ADH has an affinity about 20- 
fold higher for ethanol than for methanol (Haffner et. al., 1997; Tephly, 1991). 
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Figure 1.2: Metabolic Pathway of methanol. (1) Alcohol Dehydrogenase (ADH); 
(2) Aldehyde Dehydrogenase (ALDH); (3) Catalase-Peroxidase; (i) 
Tetrahydrofolate dependent 
 
Consequently, a simultaneous consumption of ethanol and methanol will result in 
considerable inhibition of methanol metabolism, the extent of which is dependent on 
blood ethanol levels. In chronic alcoholics, the activity of hepatic cytochrome P450 2E1, 
a key enzyme in the metabolic elimination of ethanol (Klotz & Ammon, 1998), is 
increased. This could accelerate the rate of elimination of ethanol and thereby reduce its 
protective effect in methanol-containing alcoholic drinks. The half-life of elimination of 
methanol is about 140 min, its oral absorption 100%, and its volume of distribution 
approximately equal to the total body water at equilibrium (Paine & Dayan, 2001). Small 
amounts of methanol are excreted, unchanged, in urine and expired in air. About 10% of 
the dose ingested is excreted in urine as formate.  
A blood ethanol level greater than 22 mM (100mg%) will totally inhibit the active 
catabolism of methanol. This will take a consumption of 36g of ethanol over a period of 
1 hour, followed by the continued consumption of about 6.5g/hr for about 40 hrs for 
methanol levels to be halved by normal physiological processes in the body as described 
earlier (Haffner et. al., 1997). This is, however, only seen in non-drinkers and average 
consumers of alcohol including binge drinkers. Empirical observations indicate that a 
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blood methanol level exceeding 3.24 mM (20mg%) is high enough to produce a clinical 
toxicity to justify treatment. A concentration of 3.24 mM is at the border of severe illness. 
A level of 0.16 mM (1mg%) is normal and levels of 0.810 mM (5mg%) are tolerated 
without evidence of any clinical disorder (Jacobsen et. al., 1988; Paine & Dayan, 2001).  
The body produces methanol as well. Several workers have described an 
endogenous production of methanol (Iffland & Staak, 1990; Roine et. al., 1989; Sarkola & 
Eriksson, 2001). Endogenously produced methanol levels are sufficiently low (0.016 mM 
to 0.045 mM; 0.07 – 0.2 mg/100 ml) that they would normally go undetected by 
analytical procedures routinely employed in clinical laboratories (Gilg et. al., 1987). Kapur 
and Maziar (Kapur & Maziar, 1993) observed significantly higher formate levels in three 
methanol positive patients. This would imply a continued presence of methanol and 
formate in the plasma of alcoholics. Such an exposure would probably increase the risk 
of organ and tissue damage including that of the fetus. 
 
1.2 Effects of Alcohol Abuse: Fetal Alcohol Spectrum Disorder (FASD) 
1.2.1 Definition of Fetal Alcohol Spectrum Disorder 
The disorders associated with alcohol consumption during pregnancy known as 
fetal alcohol spectrum disorder (FASD) consist of a wide spectrum of effects ranging 
from mild, known as fetal alcohol effects (FAE) or alcohol related neuro-developmental 
disorders (ARND), to extreme manifestations known as full blown fetal alcohol spectrum 
disorder (FASD). Smith and Jones (Jones & Smith, 1973) first described the distinct 
dysmorphic condition associated with maternal alcohol abuse during pregnancy known as 
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FASD. Fetal alcohol spectrum disorder (FASD) consists of a pattern of anomalies 
occurring in the babies born to drinking women and consists of (a) pre- and/or postnatal 
growth retardation, (b) morphological anomalies, and (c) central nervous system (CNS) 
dysfunction (Hannigan et. al., 1992; Rosett, 1980; Streissguth, 1986; Hannigan et. al., 
1992). The mild form of FASD includes an incomplete picture of nonspecific physical 
and psychological manifestations of neurodevelopmental deficits following alcohol 
exposure and was originally termed as fetal alcohol effect (FAE), also known as atypical 
FASD. This (FAE) was later replaced by the term alcohol-related birth defects (ARBD) 
and/or alcohol-related neurodevelopmental disorder (ARND) (Stratton and Battaglia, 
1996). The effects of ARBD and ARND can be just as severe as full blown FASD (Abel, 
1999b). The term FASD is a new umbrella term that encompasses the full range of 
effects and conditions that range from mild, such as FAE, ARBD and ARND, to severe 
(full-blown FASD). 
 
1.2.2 Prevalence of Fetal Alcohol Spectrum Disorder 
Fetal alcohol spectrum disorder (FASD) is a medical, social and economical 
catastrophe of great magnitude. Fetal Alcohol Spectrum Disorder in newborns is under-
recognized due to the absence of many of the manifestations of fetal alcohol exposure, 
which usually appear with age (Stoler and Holmes, 1999; Canadian Pediatric Society, 
2002). It is now recognized as a leading nongenetic cause of mental retardation (Abel & 
Sokol, 1986). It has been estimated that the incidence of full-blown FASD is between 
2.8/1000 and 4.8/1000 live births. The incidence of a combination of FASD is estimated 
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to be at least 9.1/1000 live births (Sampson et. al., 1997). Abel (Abel & Hannigan, 1995; 
Abel, 1995) estimated the incidence of FASD among “heavily” drinking women (as 
defined by consumption of 5 or more drinks per occasion, an average of 2 or more 
drinks per day, a positive MAST score, or a clinical diagnosis) at about 4.3% of all live 
births. In one community in British Columbia, Robinson et. al., identified 22 of 116 
children (16%) as having FASD (Robinson et. al., 1987). MacDonald (1991) suggested a 
rate of 3.3/1000 children in British Columbia and a rate of atypical FASD of up to five 
times as high if older children with the syndrome were included. This means that based 
on 42,909 births per year in 1998 (BC vital Statistics, 1998) 142 infants were born with 
FASD and 710 infants were born with atypical FASD per year in British Columbia. In 
northern Manitoba, Williams and coworkers (Williams et. al., 1999) estimated incidence of 
FASD to be 7.2/1000 children based on physical findings at birth. However, he points 
out that a number of cases might have been missed. Lupton, Burd and Harwood (Lupton 
et. al., 2004) found that physical signs of FASD are not as physically apparent until 4 years 
of age, and therefore, diagnoses made based on birth records will only catch the most 
severe cases and will miss the others. Although all races are susceptible, FASD is found 
in disproportionately higher frequencies in Native American Populations (Aase, 1981; 
Macdonald, 1991; Williams et. al., 1999). The incidence of FASD is much higher in other 
communities outside of North America. For example, the rate of FAS found in South 
Africa is 65.2-74.2 per 1,000 children in the first grade population (33-148 times greater 
than U.S. estimates). This is the highest yet reported in any overall community in the 
world (Viljoen et. al., 2005). 
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Many women who drink continue to do so into the pregnancy. This could be due 
to lack of understanding of alcohol’s detrimental effect to the fetus, whereas alcohol 
dependent women may be unable to abstain. Those who intend to abstain during 
pregnancy, however, may consume alcohol in early gestation before they realized were 
pregnant. In Canada there is increasing awareness of the extent of FASD in Native 
communities. 
 
1.2.3 Fetal Alcohol Spectrum Disorder and Binge Drinking 
Binge drinking is defined as a pattern of drinking alcohol that brings blood alcohol 
concentration (BAC) to 0.08 gram percent (g%) or above (National Institutes of Health, 
2004). For the typical adult, such a pattern corresponds to consuming 5 or more drinks 
for males, or 4 or more drinks for females, in approximately 2 hours. A drink is defined 
as one containing the equivalent of 0.6 oz (17.74 mL; 14g) of pure alcohol (National 
Advisory Council on Alcohol Abuse and Alcoholism, 2004). It is evident that binge 
drinking results in higher BAC than with peak BAC achieved with continuous drinking.  
Since Alcohol dehydrogenase is a saturable enzyme at higher alcohol levels, 
metabolism of alcohol does not keep up with intake (Jones & Sternebring, 1992; Kitson, 
1996). Therefore, binge drinking not only leads to elevated BAC but also prolonged 
exposure, factors that could lead to fetal adverse effects (Abel & Hannigan, 1995). This is 
particularly important in unrecognized pregnancies where the mother might be engaged 
in binge drinking during a time in which the fetus is most susceptible to the harmful 
effects of alcohol (Abel, 1999b; Chaudhuri, 2000b; Day & Richardson, 1991).  
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Alcohol consumption amongst women is high with 4% being considered alcohol 
dependent (Bloomfield et. al., 2006; Bluthenthal et. al., 2005; Chambers et. al., 2005). A 
study conducted by Chambers et. al. (Chambers et. al., 2005) found 43% of 100 pregnant 
low-income Latinas surveyed reported some alcohol use in the 3 months prior to 
pregnancy with 20% reporting at least one binge episode of 4 or more standard drinks 
during that time frame; 5% reported drinking 7 or more drinks per week; 8% continued 
drinking alcohol after recognition of pregnancy. Frequency of periconceptional alcohol 
use did not differ between women who planned or did not plan the pregnancy in the 
study.  The study also found that awareness of alcohol warning messages and/or 
knowledge of the FASD was significantly correlated with alcohol consumption in the 
periconceptional period. The investigators also found that predictors of alcohol use in the 
periconceptional period included English language/higher level of acculturation, younger 
maternal age, lower parity, higher level of education and, younger age at first drink and 
having ever smoked. 
 
1.2.4 Biochemical Aspects of Fetal Alcohol Spectrum Disorder 
Evidence from epidemiological studies has shown that there is a selective presence of 
FASD in certain populations indicating that fetal alcohol spectrum disorder is not an equal 
opportunity disorder (Abel & Hannigan, 1995; Abel, 1995; Abel & Sokol, 1991; Abel & 
Sokol, 1987). On the basis of the disparities in the occurrence of FASD, Abel and 
Hannigan drew inferences about potential socio-behavioral risk factors for FASD that they 
called “permissive” factors. These are alcohol intake pattern, race and socioeconomic 
status, culture, and smoking. They argued that these factors provide the context within 
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which vulnerability to alcohol’s teratogenic effects are increased. The permissive factors 
create a biological milieu that is “provocative” for FASD. Examples of “provocative” 
factors are increased blood alcohol levels (BAL), under-nutrition, environmental pollutants, 
psychological and physical stress, and increased drug levels in the body. The provocative 
factors increase cellular susceptibility to alcohol’s toxic effects, which are thought to occur 
through hypoxia and free radical damage (Abel & Hannigan, 1995). 
 
Alcohol Consumption by 
pregnant mother  
 
Ethanol in maternal & fetal 
blood 
 
 
 
Actaldehyde formation in the 
fetus  
 
 
Generation of free radicals & 
altered growth factors in the 
fetus
 
 
Figure 1.3: Mechanism of action of the deleterious effects of alcohol in the developing 
fetus. 
 
Prenatal alcohol exposure can have a variety of consequences ranging from death 
or FASD at one end of the spectrum, to relatively normalcy at the other end. Evidence 
from autopsy and magnetic resonance imaging studies have illustrated microcephaly, with 
tissue loss, cerebral dysgenesis, and abnormal neural migration and glial cells in children 
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with full-blown FASD (Roebuck et. al., 1998). Holoprosencephaly, a condition associated 
with the failure of the brain to divide into two hemispheres leading to 
neurodevelopmental and facial abnormalities, is a characteristic feature of full-blown 
FASD. Other abnormalities include that of the brainstem, cerebellum (especially of the 
anterior vermis), corpus callosum such as agenesis and hypoplasia, absence of olfactory 
lobes, absent or hypoplastic caudate nuclei and, hypoplasia of the hippocampus 
accompanied by abnormal or absent basal ganglia. There are findings from positron 
emission tomography that have demonstrated glucose metabolism abnormalities, 
especially in the anterior caudate nucleus and vermis of the cerebellum, even in the 
absence of overt structural abnormalities (Indian and Inuit Health Committee, 2002).  
 
1.2.5 Clinical Diagnosis and Treatment 
The diagnosis of FASD is based on a triad of clinical features (Table 1.3) in an 
individual exposed to alcohol in utero. This triad consists of pre- and postnatal growth 
deficiency, a characteristic pattern of CNS dysfunction and facial abnormalities (Astley & 
Clarren, 2002; Indian and Inuit Health Committee, 2002; Roebuck et. al., 1998). Perhaps 
the most devastating sequelae of FASD are the neurobehavioural manifestations, 
associated with alcohol’s effect on the CNS (Roebuck et. al., 1998). Central nervous 
system dysfunction leads to primary disabilities which are manifested in a number of 
ways, including: compromised intelligence (IQ 50-115), language, learning and memory; 
abnormal activity, attention (in the form of Attention Deficit Disorder), and behaviour 
(Indian and Inuit Health Committee, 2002). Secondary disabilities in FASD individuals 
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include mental health problems, disrupted school experiences, trouble with the law and 
incarceration, inappropriate sexual behavior, and drug and alcohol abuse problems. 
Considerable neurological development occurs postnatally. If child care, nutrition, 
and surrounding environment are adequate, it is probable that FASD children can make 
considerable progress in leading a normal life. This is particularly true in mildly affected 
individuals. For example, treatment regiments enable the clinical management of FASD 
and include behavioral interventions (Klintsova et. al., 1998), special education programs 
and stimulants. Intensive case management of drinking mothers has been shown to 
prevent women from having additional children with drug and/or alcohol exposure 
(Ernst et. al., 1999; Grant et. al., 1999).  
Therefore, the most desirable way of dealing with FASD is through abstinence 
before, and after, conception. However, once a diagnosis of FASD is made measures 
must be put in place, as described earlier, that involves coordination of several levels of 
identification, intervention, and treatment in order to maximize the child's postnatal 
development. With adequate education and protection from negative child rearing 
environments and attention to predictable crises at various developmental stages, can 
make the difference between achieving a reasonable degree of independence and life 
satisfaction and more negative outcomes in FASD individuals (Campbell & Ramey, 
1994). 
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Table 1.3: Diagnostic Criteria for Fetal Alcohol Spectrum Disorder. (Modified 
from Stratton & Battaglia, 1996 and Warren & Foudin, 2001.) 
 
*Defined as a pattern of excess alcohol intake characterized by substantial, regular 
intake or by binge drinking; CNS = Central Nervous System; FASD = Fetal Alcohol 
Spectrum Disorder. 
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1.3 Role of Vitamins and Other Cofactors in Formate Metabolism 
1.3.1 Folic Acid 
 
 
Figure 1.4: Deprotonated molecule of folic  acid 
Folic acid (Figure 1.4) is a vitamin and a cofactor in the elimination of formate. It 
plays a major coenzymatic role in one carbon metabolism. The principal function of 
folate coenzymes is to accept or donate one-carbon units in folate-requiring metabolic 
pathways. Thus, folic acid is a key participant in the biosynthesis of DNA and RNA, and 
the methylation of transfer RNA and certain amino acids (Wagner, 1995) (Figures 1.5 and 
1.6). Thus, the requirement for folate by the body is related to the cellular reproduction 
occurring at any particular time (Wagner, 1995). One such time of an increased folate 
requirement is during pregnancy when there is an enormous increase in cellular 
proliferation as a result of uterine enlargement, expansion of blood volume, placental 
development and fetal growth. The folate molecule that acts as an acceptor of carbon in 
the one-carbon cycle is in the polyglutamyl form of tetrahydrofolate (THF) (Wagner, 
1995) 
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Figure 1.5: Overview of one-carbon metabolism and transsulfuration pathways. 
Abbreviations: Ado, adenosyl; CH3-THF, 5-methyl-THF; DHF, dihydrofolic 
acid; dTMB, deoxythymidine monophosphate; dUMP, deoxyuridine 
monophosphate; FAD, flavin adenine dinucleotide; 10-HCO-THF, 10-
formyl-THF; PLP, pyridoxal phosphate; THF, tetrahydrofolate.  
 
The 3-carbon of serine acts as a major carbon source in the conversion of THF to 
5,10-methylene-THF, a crucial first step in the metabolism of folate (Figure 1.5). This 
one-carbon unit is transferred from serine to THF via pyridoxal phosphate (PLP)-
dependent serine hydroxymethyltransferase (SHMT) to form 5,10-methylene-THF and 
glycine. Thus, a portion of the 5,10-methylene-THF produced undergoes irreversible 
enzymatic reduction to the methyl oxidation state (as 5-methyl-THF) by methylene 
tetrahydrofolate reductase (MTHFR). The N-5 methyl group of 5-methyl-THF can only 
be used metabolically for transfer to homocysteine, which results in the 
generation/regeneration of methionine. The enzyme MTHFR plays a key role in one-
carbon metabolism. Its catalytic action results in the conversion of methylene-THF to 5-
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methyl-THF, thus irreversibly directing the one-carbon moiety to methylation of 
homocysteine synthesis. Between 50 and 80% of the homocysteine generated is re-
methylated, depending on the dietary content of methionine and choline (Bailey & 
Gregory, III, 1999).  
The methionine synthase reaction involves removal of a methyl group from 5-
methyl-THF, which is sequentially transferred to the vitamin B-12 and then to 
homocysteine (HCY) to form methionine. Other than for protein synthesis, methionine 
serves as a methyl group donor through conversion to S-adenosylmethionine (SAM), a 
key biological methylating agent involved in over 100 methyltransferase reactions with a 
wide variety of acceptor molecules. This methionine synthase reaction also regenerates 
THF, which is required for the formation of 5,10-methylene-THF and 10-formyl-THF. 
These substances are used directly in thymidylate and purine synthesis, respectively. In the 
thymidylate synthase reaction, 5,10-methylene-THF donates its methyl unit (becoming 
the thymidine methyl group). In the de novo purine synthesis pathway, two separate steps 
utilize 10-formyl-THF (Bailey & Gregory, III, 1999).  
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Figure 1.6: An overview of one-carbon metabolism and transsulfuration pathways. SAM, 
adenosylmethionine; SAH, adenosylhomocysteine; dTMP, deoxythymidine 
monophosphate; B12, vitamin  B 12; B6, vitamin  B6; MS, Methionine 
synthase; CBS, Cystathionine β-synthase; CT, Cystathionase; MTHFR, 
Methylenetetrahydrofolate reductase. 
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Since the synthesis of methyl groups and other one-carbon units is tightly 
controlled (Shane, 1995; Wagner, 1995), the coenzymes involved in folate metabolism are 
compartmentalized between the cytosol and the mitochondria. While the metabolic 
products of these reactions are readily transported between compartments, the folate 
coenzymes are not. Under most circumstances the cytosolic form of S-
hydroxymethyltransferase (SHMT) is thought to function in the transfer of carbons from 
serine to THF, yielding 5,10-methylene-THF. The mitochondrial form of SHMT is 
thought to convert glycine to serine and to serve as a source of mitochondrial THF 
(Garcia-Martinez & Appling, 1993; Kastanos et. al., 1997). In contrast to one-carbon 
metabolism in cytosol, the mitochondrial one-carbon metabolism derives much of the 
one-carbon transfer from folate-mediated serine oxidation (to formate) rather than via 
SHMT (Graham et. al., 1997). The carbon transfer from serine to THF by SHMT is 
inhibited by 5-methyl-THF and by 5-formyl-THF (Stover & Schirch, 1991). The 5-
formyl-THF is formed in a secondary reaction catalyzed by SHMT (Stover & Schirch, 
1990). S-adenosylmethionine regulates this pathway by inhibiting MTHFR, which 
suppresses the production of 5-methyl-THF. Therefore, the intracellular presence of 
excess methyl groups (such as 5-methyl-THF and SAM during periods of high of 
methionine and choline intake, and adequate supply of other relevant coenzymes) 
prevents the further de novo biosynthesis of methyl groups (Bailey & Gregory, III, 1999).  
The influence of intracellular folate concentrations (as governed largely by dietary 
intake) on the entry and processing of substrate in one-carbon metabolism is uncertain 
(Bailey & Gregory, III, 1999). Since folates in the body serve as carbon acceptors, carriers, 
and donors, a severe folate deficiency can impair one-carbon metabolism (Miller et. al., 
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1994). However, because of the role of 5-methyl and 5-formyl-THF as SHMT inhibitors, 
marginal folate deficiency may (at least transiently) have little adverse effect on carbon 
flux because the effects of these physiologic inhibitors are diminished. Flux through 
SHMT can be predicted to be a function of pyridoxal 5’-phospahte (PLP) concentrations 
(Jones, III & Priest, 1978). In situations of poor folate status, S-adenosylhomocysteine 
(SAH) concentrations increase due to the impairment of methyl group synthesis and 
homocysteine re-methylation. Inhibition by the resulting product (SAH) suppresses many 
of the SAM-dependent methyltransferase reactions (Selhub & Miller, 1992). This 
illustrates the far-reaching effects of impaired one-carbon metabolism during nutritional 
deficiency. Although other sources of one-carbon units exist (e.g., choline, formate, 
glycine or betaine), serine appears to be the primary carbon donor for the diverse 
processes of one-carbon metabolism (Pasternack et. al., 1996; Shane, 1995; Wagner, 
1995). 
The important role of folate in one carbon metabolism is underscored by the fact 
that maternal folate status can modulate the developmental toxicity of methanol (Fu et. 
al., 1996; Sakanashi et. al., 1996). Sakanashi and coworkers (Sakanashi et. al., 1996) also 
found a correlation between fetal body weights and increased incidence of cleft palate in 
methanol treated CD-1 mice with low folic acid levels. Thus, raising folic acid 
consumption can reduce the risk of having a neural-tube defect (NTD) pregnancy (Wald 
et. al., 2001), although evidence points to the fact that maternal Hcy levels are the primary 
predictor of fetal blood Hcy (Molloy et. al., 2002).  
In 1996 the United States Food and Drug Administration (FDA) issued a 
regulation requiring all enriched grain products to be fortified with folic acid to reduce 
  28
the risk of neural-tube defects in newborns. This led to a fortification of 140 µg of folic 
acid per 100g of grain. Canada introduced a similar law in 1998. Wald and coworkers 
(Wald et. al., 2001) studied the effect of folic acid supplementation on serum folate. They 
found an increase in serum folate level of 0.94ng/ml (95% CI 0.77-1.10) for every 0.1 
mg/day increase in folic acid intake in women aged 20-35 years, and about double that in 
women aged 40-65. They concluded that women planning a pregnancy should take 5mg 
folic acid tablets daily, instead of the 0.4mg dose presently recommended. 
The need for increased folic acid intake is concurred by other investigators 
(Feinleib et. al., 2001; Siega-Riz et. al., 2002) who state that a large proportion of women 
of childbearing age are still not consuming folic acid at recommended levels. 
Supplemental folic acid (monoglutamate form) (Figure 5.2) has a higher bioavailability 
(1.7 times) compared to folate from dietary sources (Feinleib et. al., 2001). 
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1.3.2 Vitamin B6 
 
 
Figure 1.7: Structures of different forms of vitamin  B6 
 
Vitamin B-6 is a water-soluble vitamin that exists in six forms: pyridoxal (PL), 
pyridoxine (PN), pyridoxamine (PM); and their phosphate derivatives, pyridoxal 5'-
phosphate (PLP), pyridoxine 5'-phosphate (PNP), and pyridoxamine 5'-phospate (PNP) 
(Figure 1.7). Pyridoxine is found in foods as a glycoside or in free form. The glycoside 
form is hydrolyzed by luminal enzymes and/or microflora before absorption in the 
jejunum by a process that is non-saturable. Pyridoxal 5'-phosphate is the active coenzyme 
form and also the most significant in human metabolism (Leklem, 1991). Pyridoxal 5'-
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phosphate plays a vital role in the functions of more than 100 enzymes that catalyze 
essential chemical reactions (Leklem, 1991; Leklem, 1999). Vitamin B-6 is an essential 
vitamin because the body cannot synthesize it and its coenzyme. However, severe 
deficiency of vitamin B-6 is uncommon. Due to a poor diet and impaired metabolism of 
vitamin B-6, alcoholics are thought to be most at risk of deficiency of vitamin B-6 
(Holman, 1995). 
The conversion of PN, PL and PM to their respective phosphate forms is a 
crucial step in the metabolism of vitamin B-6. A single kinase enzyme catalyzes the 
conversion, which in the brain and liver is dependant on zinc. The erythrocyte kinase is 
most active with cobalt or manganese. A flavin-dependent oxidase converts PNP and 
PMP to PLP (Figure 1.7).  
The liver is the major source of plasma PLP. During conditions of increased 
muscle turnover such as in moderately severe exercise, circulating levels of PLP can 
increase as well. Pyridoxal 5'-phosphate must be dephosphorylated before being taken by 
cells and then rephosphorylated within the cell (Figure 1.8). This occurs because PLP 
does not cross membranes. The major determinant of plasma PLP is the balance of two 
pathways: the liver formation of PLP and, its breakdown by alkaline phosphatase. Tissues 
use PL released in the circulation as needed. The liver takes up the excess where it is 
degraded to pyridoxic acid for excretion by the kidneys. About half of the dietary intake 
of B-6 is excreted in this way. Urinary excretion, therefore, reflects vitamin intake rather 
than body reserves. 
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Figure 1.8: A simplified overview of vitamin B-6 metabolism and transport. PL = 
Pyridoxal; PN = Pyridoxine; PM = Pyridoxamine; PLP = Pyridoxal 5’-
phosphate; PNP = Pyridoxine 5’- phosphate; PMP = Pyridoxamine 5’-
phosphate; RBC = Redblood cell. (Modified from Holman, 1995) 
 
Increased levels of PLP are encountered in patients with hypophosphatasia, an 
inborn error of metabolism characterized by deficient alkaline phosphatase activity 
(Holman, 1995). Abnormally low levels of PLP occur in patients with chronic renal 
failure and those on dialysis or with kidney transplants. Alcohol also reduces hepatic 
reserves of PLP, most likely due to accelerated hydrolysis by alkaline phosphatases. 
Deficiency of pyridoxine can also cause sideroblastic anemia.  
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Homocystinuria, an inborn error of vitamin B-6 dependent metabolism, is one of 
the disorders of amino acid metabolism characterized by increased concentration of Hcy 
in the plasma (Holman, 1995). Symptoms of the disease, due to the accumulation of 
homocysteine, in adults include dislocation of the eye lens, thrombosis, mental 
retardation and abnormal skeletal formation. About 50% of the patients, however, 
respond to vitamin B-6 doses of up to 1500 mg/day. For some unresponsive patients, 
administration of Betaine, which is a methyl donor in the methylation of homocysteine to 
methionine, may be helpful (Holman, 1995). Other vitamin B-6 dependent inborn errors 
of metabolism include cystathioninuria, xanthurenic aciduria, hyperglycinemia and 
histidinemia. 
Normal plasma or serum values of vitamin B-6 range from 20-121 nM, 
depending on body requirements and method of detection. Values of < 14 nM are 
indicative of a deficiency, and patients with levels of 15 – 20 nM are considered to be 
marginally low in vitamin B-6 (Deitrick et. al., 2001; Holman, 1995). In pregnancy, levels 
of vitamin B-6 are often lower (Contractor & Shane, 1970). Cases of maternal deficiency 
may be excerbated by toxemia or hypermesis gravidum (severe vomiting) (Shane & 
Contractor, 1980). Moretti and coworkers (Moretti et. al., 1982) found that high doses of 
the vitamin are antilactogenic, although a typical multivitamin supplementation elevates 
plasma and milk PLP without reducing prolactin or lactation (Andon et. al., 1976). 
 
1.3.3 Vitamin B12 and Methylmalonic Acid 
Vitamin B-12 consists of a family of substances composed of tetrapyrrole rings 
surrounding a central cobalt atom with nucleotide side chains attached to the cobalt 
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(Figure 1.9). The name cobalamin is the name given to the overall group, with each of the 
different upper axial ligand links of cobalt conferring a different name (e.g., 
methylcobalamin for the methyl moiety; hydrocobalamin for hydroxyl moiety; 
aquacobalamin for H2O moiety; cyanocobalamin for cyanide; 5-deoxyadenosylcobalamin 
for 5-deoxyadenosine). The human body is incapable of synthesizing the corrin ring 
structure (see Figure 1.9), and so humans are completely dependent upon dietary sources 
of vitamin B12. One of the most commonly supplemented forms of vitamin B-12 is 
cyanocobalamin (CN-Cbl). Humans have to remove and detoxify the cyanide molecule, 
although at this level it’s toxicologically insignificant. The resulting cobalamin, (Cbl), from 
the cleavage of CN-Cbl, is then reduced to its usable +1 oxidation state. This is followed 
by conversion to one of the two metabolically active coenzyme forms: 
adenosylcobalamin (AdenosylB12) and methylcobalamin (MethylB12) (Pezacka et. al., 
1990).  
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Figure 1.9: Structure of Cobalamin (vitamin  B-12) 
 
Absorption of vitamin B-12 from the gastrointestinal tract requires the formation 
of a complex between dietary cobalamins and R-proteins, and also the secretion of 
intrinsic factor by the stomach parietal cells. Pancreatic enzymes in the small intestine 
cleave the cobalamin-R-protein complex. The released cobalamin molecule binds with 
intrinsic factor where it is absorbed in the distal ileum. Cobalamin is then detached from 
intrinsic factor in the enterocyte cells of the small intestine, and is bound to 
transcobalamin II for transport into tissues (Figure 1.10).  
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Figure 1.10: Digestion, absorption and transport of vitamin  B-12. B12 = vitamin  B12; 
HCl = Hydrochloric acid; IF = Intrinsic factor; HC = Haptocorrin; PE = 
Pancreatic enzyme; TC = Transcobalamin. (modified from Axis-Shield, 
2002. www.active-b12.com/b12-deficiency/general.php) 
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Adenosylcobalamin (also referred to as coenzyme B12, cobamamide, cobinamide, 
or dibencozide) is the major form of vitamin B-12 in cellular tissues, and is retained in the 
mitochondria. MethylB12 is predominantly found in plasma, certain other body fluids 
(such as cerebral spinal fluid), and cytosol (Gregory Kelly, 2002). AdenosylB12 is 
important in carbohydrate and lipid metabolism as well as in the synthesis of porphyrin. 
It mediates the mitochondrial conversion of methylmalonyl-CoA to succinyl-CoA. This 
reaction is catalyzed by methylmalonyl-CoA Mutase, which then enters the tricarboxylic 
acid (TCA) cycle (Qureshi et. al., 1994). Hence, deficiency of adenosylB12 leads to 
accumulation of methylmalonic acid, MMA (Figure 1.11).  
 
Figure 1.11: Metabolic pathway of adenosylcobalamin (AdenosylB12) and 
methylcobalamin (MethylB12). THF = Tetrahydrofolate; MethylTHF = 
Methyltetrahydrofolate; MS = Methionine synthase; MMA = Mehtylmalonic 
acid. (modified from Axis-Shield, 2002. www.active-b12.com/b12-
deficiency/general.php) 
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Under normal conditions, MMA is present in physiological fluids at very low 
concentrations. In methylmalonic acidemia, a condition arising due to an inborn error of 
metabolism leading to disorders of vitamin B12 metabolism, the concentration of MMA 
becomes significantly elevated. Normal serum methylmalonic acid levels are 0.08 to 0.56 
µmoles/L. Urine levels are less than 4.7mg/mg creatinine Values greater than these 
normal range suggest vitamin B12 deficiency or a genetic disease resulting in high levels 
of methylmalonic acid (methylmalonic aciduria). 
The metabolism of MMA occurs in the mitochondria and is catalyzed by 
methylmalonyl CoA mutase, one of only two known B12-requiring reactions, and the 
only one to occur in mitochondria (Figure 1.11). Methylmalonic acidemia has been 
attributed to the disruption of this reaction, resulting in associated neurological 
symptoms and learning deficiencies. Another contributing factor to methylmalonic 
aciduria may be the secondary accumulation of propionyl CoA. Propionyl CoA acts as a 
substitute for acetyl CoA in the citrate synthase reaction and forms methyl citrate, a TCA 
cycle poison. Due to their high oxidative demands, neural tissues are highly sensitive to 
the build-up of methyl citrate (Bralley & Lord, 1999). 
In humans methylB12 acts as a cofactor for the enzyme methionine synthase (see 
Figure 1.6) found in the cytosol. Therefore, elevated levels of homocysteine and 
methylmalonic acid, MMA (leading to methylmalonic acidemia) can be used as 
biomarkers of decreased levels of the coenzyme forms of vitamin B12 (TC-B12), or the 
presence of a genetic enzyme defect. Since methylB12 is a potential donor of the methyl 
group in the regeneration of methionine from homocysteine, this argument can be used 
to justify this coenzyme form of vitamin B12 as a part of the nutritional protocol for 
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lowering homocysteine. Araki et al demonstrated this point by administering 1000 µg of 
MethylB12 i.m. daily for three weeks to ten diabetic patients with elevated plasma 
homocysteine levels. The plasma levels of homocysteine decreased following treatment 
from a mean value of 14.7 to 10.2 nmol/ml (P < 0.01) (Araki et. al., 1993). Bhatt and 
coworkers (Bhatt et. al., 1986) also suggested that adenosylB12 be the cobalamin therapy 
of choice for individuals with biochemically uncharacterized methylmalonic acidemia 
after successful treatment of methylmalonic patients with AdenosylB12. Although it is 
not unusual to have high blood levels of vitamin B12, patients with hepatitis, cirrhosis, 
and other liver diseases have low liver concentrations of vitamin B12 and its coenzymes. 
This is due to an impaired ability of the liver to absorb vitamin B12 from the portal 
circulation (Glass et. al., 1958). 
 
1.3.4 Homocysteine 
Biochemical signs of subclinical folate deficiency can be demonstrated by 
measurement of plasma total homocysteine (tHcy). This is because plasma tHcy is a 
functional marker of the activity of the enzymes involved in the retroconversion of Hcy 
to methionine and its conversion to cystathione, which is dependent on vitamin B6 status 
(Van der Dijs et. al., 2002) (Figure 1.6). Folate and vitamin B12 act as a substrate for 
methionine synthase and 5, 10-methylenetetrahydrofolate reductase (MTHFR). Thus, 
homocysteine is an intermediate product in the metabolism of methionine. In healthy 
individuals, two different pathways are utilized to metabolize homocysteine. One 
pathway leads to the conversion of homocysteine back to methionine and is dependent 
on folate and vitamin B 12. The other pathway results in the conversion of homocysteine 
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to cysteine. This pathway requires two vitamin B-6 (PLP)-dependent enzymes. Therefore, 
the level of homocysteine in the blood is regulated by at least three vitamins: folic acid, 
vitamin B-12, and vitamin B-6 (See Figure 1.6). Studies have shown a link between 
elevated Hcy and vascular disorders, a link that is biologically plausible since Hcy 
promotes oxidant injury to the vascular endothelium, impairs endothelium-dependent 
vasomotor regulation and may also alter the coagulant properties of the blood. The high 
plasma Hcy levels can be reduced by dietary supplements of folic acid and other B 
vitamins (Maxwell, 2000). 
Bonnette and co-workers (Bonnette et. al., 1998) found that plasma Hcy 
concentrations were significantly lower (mean Hcy concentration 60% lower) in normal 
pregnant women during the second trimester than in non-pregnant women, independent 
of folate intake (5.4 µM compared to 8.7 µM). Possible explanations for these lower 
levels include dilution of maternal blood secondary to plasma expansion. While the 
increased gestational blood volume begins around the sixth (6th) week of pregnancy and 
peaks at 30-34 weeks, hematocrit decreases during the second week to 33-39% 
(Blackburn & Loper, 1992). Another explanation is that the hormonal milieu might 
contribute to lower plasma Hcy concentrations, especially in the second trimester. This 
explanation is based on the fact that plasma Hcy levels are lower in premenopausal 
women compared to postmenopausal women (Van der Mooren et. al., 1997; Wouters et. 
al., 1995).  
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1.3.5 Methionine, S-adenosylmethionine and S-Adenosylhomocysteine 
H2N CH C
CH2
OH
O
CH2
S
CH3  
Figure 1.12: Structure of the amino acid Methionine. 
Methionine (Figure 1.12) is a sulfur-containing essential amino acid. It reacts with 
adenosine triphosphate (ATP) to form S-adenosyl methionine (SAM), a potent donor of 
methyl groups (Figures 1.6). S-adenosylhomocysteine (SAH) is formed as a result of 
methyl transfer to other R-CH3 groups (in catecholamines, DNA, RNA, etc) (Figure 
1.11). S- adenosylhomocysteine (SAH) is then cleaved by the enzyme 
adenosylhomocyteinase to yield homocysteine and adenosine. The retroconversion of 
Hcy to methionine is catalyzed by methionine synthase, a reaction that occurs under 
methionine-sparing conditions and requires N5-methyl-tetrahydrofolate as methyl donor. 
Regulation of the methionine metabolic pathway is based on the availability of 
methionine and cysteine. If both amino acids are present in adequate quantities, SAM 
accumulates and is a positive effector on cystathionine synthase, encouraging the 
production of cysteine and α-ketobutyrate (both of which are glucogenic). However, if 
methionine is scarce, SAM will form only in small quantities, thus limiting cystathionine 
synthase activity. Under these conditions accumulated homocysteine is re-methylated to 
methionine, using N5-methylTHF and other compounds as methyl donors. 
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Figure 1.13: Metabolic pathway of methionine and its utilization in the synthesis of 
cysteine. SAM = S-adenosylmethionine; THF = Tetrahydrofolate; 
MethylTHF = Methyltetrahydrofolate. 
 
Circulating levels of 5-MTHF regulate hepatic methionine metabolism. As 
illustrated in Figures 1.6 and 1.13, this is achieved through the retro conversion of Hcy to 
methionine. Folate deficiency in the presence of ethanol consumption enhances the 
imbalance in methionine metabolism and DNA damage (Halsted et. al., 2002b). Prior 
studies have shown that methionine synthase and SAM are reduced with compensatory 
increase in betaine-homocysteine methyltransferase (BHMT) in animals chronically fed 
ethanol (Barak et. al., 1987; Halsted et. al., 2002d; Trimble et. al., 1993).  
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1.3.6 Methylglyoxal 
Methylglyoxal (MG) and glyoxal (GL) are reactive α-oxoaldehydes formed as a by-
product of glycolysis, lipid and amino acid metabolism (Thornalley, 1993). Both MG and 
GL undergo glycation with proteins by forming a covalent bond in a nonenzymatic 
reaction with free amino groups to form a schiff base (Kasper et. al., 2000; Thornalley et. 
al., 1999). The Schiff base then undergoes rearrangement to form relatively stable 
ketoamines known as Amadori products. The glycated biomolecules then undergo 
progressive dehydration, cyclization, oxidation and rearrangement to form advanced 
glycation end-products (AGEs) (Raj et. al., 2000). The glyoxals also react 
nonenzymatically with sulfhydryl (–SH) groups of membrane proteins, metabolic 
enzymes and membrane ion channels inhibiting their function. For example, GL reacts 
with arginine leading to imidazolium formation, while it reacts with lysine to form an 
AGE oxidative adduct, N-(carboxymethyl) lysine (Lee et. al., 1999; Wells-Knecht et. al., 
1995). Both GL and MG react non-enzymatically with guanyl nucleotides of DNA/RNA 
to form 6,7-dihyro-6, 7-dihydroxy-imidazo [2,3-b] purine-9 (8) one derivatives 
(Yamaguchi & Nakagawa, 1983).  
Under normal physiological conditions, methylglyoxal is kept at a low level by 
binding to cysteine and being excreted in bile and urine or through catabolism via the 
glutathione-dependent glyoxalase system (Schauenstein & Esterbauer, 1979; Schauenstein 
et. al., 1977). Therefore, any deficiencies in cysteine and/or glutathione would result in 
elevated MG.  
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1.4 Role of Free Radicals and Antioxidant Capacity 
Free radicals are chemical species that possess one or more unpaired electrons. The 
term Reactive Oxygen Species (ROS) collectively describes free radicals such as O2
•-, OH•, 
and the non-radical oxygen derivatives such as hydrogen peroxide (H2O2) and 
hypochlorous acid (HOCl). Cellular components are attacked by unstable free radicals, 
resulting in damage to lipids, proteins and DNA, thereby initiating a chain of events that 
leads to the onset of disease condition. Free radicals originate in various ways. For the 
most part, they originate from biochemical redox reactions involving oxygen, which 
occur as part of normal metabolism, e.g., O2
•-, NO•, H2O2. They may also be produced as 
part of a controlled inflammatory reaction by phagocytes, e.g., HOCl, O2
•- Occasionally, 
free radicals may be formed in response to ionizing radiation, UV light, environmental 
pollution, cigarette smoke, hypoxia, excessive exercise, and ischemia, e.g., O2
•-, OH•, 
ROO•.  
The body has a number of mechanisms that control the production of ROS and 
limit or repair their damage to tissues. These mechanisms consist of preventative actions 
and scavenging by antioxidants species. The former prevent the formation of new ROS 
and comprise of proteins such as ceruloplasmin, metallothionine, albumin, transferrin, 
ferritin, and myoglobin. The latter group of antioxidants remove formed ROS, hence 
preventing the formation of radical chain reactions. This group consists of certain 
enzymes such as superoxide dismutase, glutathione peroxidase, glutathione reductase, 
catalase, metalloenzymes, and small molecules such as glutathione, ascorbic acid, 
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tocopherol, bilirubin, uric acid, caroteniods and flavonoids. Figure 1.14 below shows a 
typical reaction of the antioxidant enzymes. 
Superoxide Dismutase (SOD) 2O2
•- + 2H+   H2O2 + O2 
Glutathione Peroxidase (GPx) ROOH + 2GSH ROH + H2O + 
GSSG 
Glutathione Reductase (GR) NADPH + H+ + GSSG NADP+ + 2GSH 
Figure 1.14: Reactions of some antioxidant enzymes. 
Alcohol induces in the liver a hyper metabolic state that is marked by increased 
mitochondrial respiration. This leads to a high rate of reoxidation of NADH, which is 
produced during the metabolism of alcohol by cytosolic alcohol dehydrogenase. The 
subsequent decrease in the NAD+/NADH ratio favours mitochondrial superoxide 
generation by increasing electron flow along the respiratory electron transport chain (Ishii 
et. al., 2003). Other reports (Colell et. al., 1998; Fernandez-Checa et. al., 1998; Fernandez-
Checa et. al., 2002) have shown that mitochondrial glutathione and SAM are important 
antioxidants in the prevention of the free radical chain reaction. 
Evidence exists that shows ethanol to have similar effects on fetal tissue. 
Henderson and coworkers (Henderson et. al., 1995) have shown that exposure to 2 
mg/mL ethanol in cultured fetal rat hepatocytes increased total and mitochondrial 
membrane lipid peroxidation products, malondialdehydes (MDA), dienes, and 
fluorescent products, as well as H2O2 production, while decreasing GSH levels. They also 
showed that some measures of this lipid peroxidation could be reversed by pre-treatment 
with vitamin E or compounds that normalized GSH stores, such as SAM and N-
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acetylcysteine. This group has shown that the same effects are evident in in vivo 
experiments. The greatest sensitivity to lipid peroxidation due to in-utero ethanol 
exposure in rats seems to reside in the earliest gestational stage (day 14). Exposure to 
ethanol at this point results in a 30% increase in membrane lipid peroxidation within 1-
hour of maternal ethanol consumption (Henderson et. al., 1995). 
Ethanol is metabolized in the liver through two pathways. The primary pathway is 
by alcohol dehydrogenase. Oxidation of ethanol by microsomal ethanol oxidizing system 
(MEOS) is the other, but minor pathway (Cederbaum, 1989). The significance of the 
MEOS pathway increases under conditions of elevated concentrations of ethanol and in 
situations of chronic alcohol consumption. In fact, Cederbaum (Cederbaum, 1989) 
indicates that the induction of this pathway is of importance from a toxicological 
perspective. This is due to the fact that the induction of the MEOS system results in the 
generation of reactive oxygen species leading to lipid peroxidation. Acetaldehyde, 
produced from the metabolism of ethanol, results in reduction of the hepatic redox state. 
It is then oxidized by the two closely related molybdo-flavo enzymes, xanthine oxidase 
and aldehyde oxidase. Both of these enzymes carry out the univalent and divalent 
reduction of O2 and the release of O2
•- and H2O2 (Fridovich, 1989).  
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Table 1.4: Suggested mechanisms for the promotion of oxidative stress by ethanol. (from 
Cederbaum, 1989. Reprinted with permission from Elsevier). 
1. Depletion of Glutahione (GSH) 
2. Altered antioxidative defence 
3. Direct toxic effect of ethanol on cell membranes and membrane fluidity 
4. Metabolic effects of ethanol via: 
i - Acetaldehyde (direct effect on cellular components) 
ii - Altered redox state  
iii - Ethanol radicals – CH3CH2O
•, CH3C
•HO, ethanol scavenges •OH/OR 
5. Ethanol induced cytochrome P450 as a Fenton/Haber-Weiss catalyst 
6. Chronic effect of ethanol via: 
i - Mitochondria injury 
ii - Microsomal proliferation and induction 
iii - Hypermetabolic state 
7. Increased hepatic iron levels 
8. Induction of release of chemoattractants 
 
Formate, the metabolite of methanol, also produces free radicals through a Fenton-
like reaction (Dikalova et. al., 2001). In this reaction, a hydroxyl radical (•OH) will be 
formed through the Fenton-like reaction, which will, in turn, oxidize formate (HCO2-), 
forming the carbon dioxide anion radical (•CO2-). The carbon dioxide anion radical then 
reacts with molecular oxygen, forming carbon dioxide and the superoxide radical (Figure 
1.15). 
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H2O2 + Fe2+   •OH  + Fe3+ + OH- 
HCO2- + •OH  •CO2-  + H2O 
•CO2-  + H2O2 CO2 + •OH + OH- 
•CO2-  + O2 CO2 + O2•- 
Figure 1.15: The generation of free radicals through the oxidation of formate.  
 
 
In addition to the induction of O2
•-, alcohol itself is able to interact with the 
hydroxyl radical, and thus, reduce the hydroxyl radical-induced toxicity (West et. al., 
1994). Ethanol also causes a decrease in hepatic GSH levels by a modest 30 to 50% 
decrease even after the short-term administration of large doses of ethanol (simulating 
binge drinking). The reduction in GSH has been observed in association with ethanol-
induced lipid peroxidation (Fridovich, 1989; Videla et. al., 1985; Videla & Valenzuela, 
1985; Macdonald et. al., 1977; Comporti et. al., 1973; Shaw, 1989). There is increased 
excretion of oxidized glutathione following chronic alcohol exposure (Sies et. al., 1979). 
Table 1.4 and Figure 1.1 summarize the suggested mechanisms by which oxidative stress 
is promoted by alcohol. 
 
1.5 Synopsis 
Methanol is present in alcoholic beverages as a congener from the manufacturing 
process. Methanol toxicity, mediated through formate, is reduced in the presence of 
ethanol due to the preferential utilization of the primary alcohol-metabolizing enzyme, 
alcohol dehydrogenase. Due to the increased activity of hepatic cytochrome P450 2E1 in 
alcoholic drinkers, the elimination of ethanol from the body is enhanced, thereby, 
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reducing the protective effect of ethanol in methanol toxicity, while increased free 
radicals such as O2
•- and reduced antioxidants (e.g., GSH) enhance oxidative stress and 
tissue injury. This could lead to fetal brain injury and development of FASD in pregnant 
women. 
Folic acid is a vitamin cofactor that is required, among other things, in the 
elimination of formate. The status of folate metabolism in the body is as equally 
important as its bioavailability in the successful elimination of formate. Folate 
metabolism, however,  is also dependent upon vitamins B-6 and B-12. Monitoring the 
levels of vitamin B-6, vitamin B-12, homocysteine, methylmalonic acid, and the folate 
catabolite p-aminobenozylglutamate and its acetamido derivative ap-
acetamidobenzoylglutamate, methionine, and its related intermediates can evaluate the 
overall status of folate metabolism. Measurements of markers of oxidative stress will 
elucidate the extent to which the toxicity of methanol and formate are mediated in the 
body in the various folate states. 
Binge alcohol drinkers may suffer from inadequate folate intake and elevated BAC. 
Inadequate folate intake, coupled to alcohol’s impairment of enterohepatic circulation of 
folic acid, could put such individuals, and especially the fetus, at risk of the toxic effects 
of formate (Figure 1.1). However, no data exists as to the true nature of the relationship 
between formate metabolism and folate status in binge drinking individuals, and how this 
relationship may affect the development of FASD. This study aimed at establishing the 
relationship between formate levels and folate status in intoxicated females. The study 
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also investigated how formate metabolism is affected during formate insult in folate 
deficient young pig. 
This study involved the recruitment of human female subjects presenting to the 
emergency room of the Royal university hospital, Saskatoon for alcohol intoxication, the 
Regina detox centre for drug and alcohol rehabilitation and the prenatal clinic of various 
hospitals of the Calgary health region. For these groups, the relationship between formate 
and folate levels was determined. Because of the difficulties and ethical considerations 
involved in studying formate kinetics in folate deficient human, an experimental folate 
deficient young swine was utilized to meet this objective. A group of these animals, 
together with their folate replete counterparts, were administered formate to assess 
formate pharmacokinetics and antioxidant capacity.  
 
1.6 Thesis Hypothesis and Objectives 
1.6.1 Overall Hypothesis 
The overall null hypothesis of this study was as follows: 
Ho: Formate does not accumulate significantly during alcohol intoxication and is unaffected by circulating 
folate levels in drinkers. Hence, antioxidant capacity is also unaffected in these individuals. 
This hypothesis was broken down into two separate (but related) components: 
 
1.6.2 Hypothesis regarding the relationship between formate and folate levels 
I. Ho: Formate levels are not increased and correlated with folate levels during intoxication in 
human females.  
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1.6.2.1 Specific Objectives 
Using human female subjects, the objectives were to determine whether: 
• blood methanol and formate levels were increased during 
intoxication 
• blood formate levels correlated with blood folate levels in alcohol 
intoxicated females. 
• blood formate levels correlated with blood folate levels in sober 
drug and alcohol rehabilitating females. 
• plasma formate levels correlated with plasma folate levels in 
pregnant females. 
• blood levels of vitamins B12 and B6, and Hcy various among the 
above mentioned groups.  
 
1.6.3 Hypothesis regarding relationship between formate pharmacokinetics 
and folate status 
II. Ho: Formate pharmockinetics is not altered during formate insult in folate deficient state.  
 
1.6.3.1 Specific Objectives 
Using folate deficient young pigs, the objectives were to determine whether: 
• formate kinetics is altered in folate deficiency during formate insult. 
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• folate utilization is altered during formate insult in folate deficiency 
state by measuring plasma levels of folate catabolites p-
aminobenzoylglutamate and its acetylated derivative ap-
acetamidobenzoylglutamate. 
1.6.4 Hypothesis regarding relationship between formate pharmacokinetics 
and Antioxidant capacity in folate deficiency state 
III. Ho: Antioxidant capacity is not altered during formate insult in folate deficiency.  
 
1.6.4.1 Specific Objective 
Using folate deficient young pigs, the objective was to determine whether: 
• plasma levels of vitamins B12 and B6, Hcy, methionine, SAM, SAH, MG 
and MMA, as markers of oxidative stress, changed during formate insult 
in folate deficient pigs. 
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CHAPTER 2 
Quantitative Endogenous Formate Analysis in Plasma and Whole Blood Using 
Headspace Gas Chromatography without Head Space Analyzer. 
2.1 Introduction 
Formic acid and its conjugate base formate are essential endogenous one-carbon 
metabolites in most living organisms participating in vital one-carbon pool of 
intermediary metabolism (Cook et. al., 2001; Fu et. al., 2001). Studies have shown that 
formate is the metabolite of methanol (MeOH) and responsible for the toxicity observed 
in methanol poisoning (Barceloux et. al., 2002; Dorman et. al., 1994; Sejersted et. al., 1983). 
Another source of formate is through the diet, environmentally through inhalation of 
methanol vapours, production by intestinal microflora and certain dietary supplements 
(Hanzlik et. al., 2005; Li et. al., 2001). For methanol toxicity to occur, it first has to be 
metabolized by alcohol dehydrogenase (ADH) to formaldehyde and thence to formic 
acid (Figure 1.2). The toxicity of formate includes optic nerve damage, an increased anion 
gap and metabolic acidosis (Medinsky et. al., 1997; Smith & Taylor, 1982).  
Early laboratory diagnosis of methanol poisoning as well as monitoring of formate 
levels, whether for occupational health or clinical research purposes, is essential. In the 
case of methanol poisoning, analysis by gas chromatographic (GC) based methods are the 
most common. Most hospitals use osmolal and anion gap to aid in their diagnosis of 
alcohol ingestion. Methanol increases the osmolal gap while formate increases the anion 
gap (Barceloux et. al., 2002; Hovda et. al., 2004; Jacobsen et. al., 1982). Metabolic acidosis 
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and increased anion and osmolal gaps might not be seen at lower concentrations of 
plasma methanol (< 20 mM) and formate (Aabakken et. al., 1994; Hovda et. al., 2004; 
Hovda et. al., 2005). Furthermore, increases in osmolal and anion gap could also be due 
to ethylene glycol ingestion (Ellenhorn et. al., 1997). Given the ‘ubiquitous’ nature of 
formate and its deleterious effect at higher levels, it is important to have a reliable 
quantitative method for the measurement of plasma formate at all levels (subclinical and 
clinical). Most routine clinical methods involve enzymatic analysis and/or GC with flame 
ionisation detection (FID). Although these methods are reliable, their sensitivity at lower 
endogenous levels is poor. Mass spectrometry may provide a better sensitivity but is 
expensive and has longer turn around due to sample preparation. We describe here a 
simple quantitative GC-FID method that is sensitive at lower formate levels and provides 
a faster turn around time.  
 
2.2 Experimental 
2.2.1 Materials 
Pure formic acid Standard (88% v/v) was obtained from Fisher Scientific (Fair 
Lawn, NJ.). Sulphuric acid and anhydrous ethyl alcohol were obtained from J. T. Baker 
(Phillipsburg, NJ., USA) and Commercial Alcohols Inc. (Brampton, ON.), respectively. A 
Gas tight syringe (Hamilton 1.25 mL; 22/2”/2) was purchased from Hamilton Company 
(Reno, NV.). A working stock solution of 100 mM formic acid was prepared in deionized 
water. Aqueous serial dilutions were made from each of the stock at concentrations of 
20.0 mM, 10.0 mM, 4.0 mM, 2.0 mM, 1.0 mM, 0.5 mM, 0.25 mM, 0.125 mM and blank. 
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A 10% (v/v) ethanol in deionised water was prepared as an internal standard. These 
working standards and the ethanol were prepared fresh each time. 
 
2.2.2 Analysis of clinical sample and Recovery experiments 
Pooled plasma was spiked with formic acid to required concentrations (0.125 and 1 
mM). Limits of detection (LOD) and quantitation (LOQ) were determined in aqueous 
samples due to the ubiquitous nature of formate in biological samples. Five levels (ten 
replicates of each) were prepared at 0.010, 0.020, 0.125, 0.250 and 1.000 mM. Data 
obtained was analysed using EP Evaluator software version 7 (David G. Rhoads 
Associates, Kennett Square, PA., USA). 
Plasma samples (personal information identifications removed) were obtained from 
69 pregnant women whose plasma samples were sent for prenatal panel (rubella Ig G, 
syphilis, hepatitis B virus antigen and HIV antigen). Another 16 and 11 serial plasma 
samples were collected from a female patient admitted into the intensive care unit for 
methanol poisoning. A further four samples were obtained from a pharmacokinetic study 
using pigs (31-38 kg, n=4), which were injected intervenously with 237 mg/kg formate.  
 
2.2.3 Sample Preparation 
Two linear calibration curves were constructed. One consisting of 0 mM, 0.125 mM, 
0.25 mM, 0.5 mM, 1.0 mM and 4.0 mM, for low formate samples. The second curve was 
constructed from standards prepared at 0 mM, 2 mM, 4 mM, 10 mM and 20.0 mM for 
high formate samples. Two hundred microlitres (200 uL) plasma samples and aqueous 
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standards were each placed in 1 mL glass vial. Fifty microlitres (50 uL) of aqueous 
ethanol (10% v/v) was added as internal standard and as a derivatizing agent. The 
formation of ethylformate was enhanced by addition to the reaction mixture of 200 uL 
concentrated sulphuric acid as a catalyst. The vials were then sealed immediately and 
placed in a waterbath for 15 minutes at 60ºC to allow the ethylformate formed to 
equilibrate in the headspace above the reaction mixture in the vial. One millilitre (1 mL) 
of this headspace gas was siphoned using a gastight syringe and injected into the gas 
chromatograph. 
 
2.2.4 Instrumentation 
Analysis of ethylformate was done on a gas chromatograph fitted with a flame 
ionisation detector (Hewlett Packard Series II 5890) fitted with a DB-ALC1 capillary 
column (30 m x 0.53 mm ID, 3.0 µm, part number J125-9134, J & W Scientific available 
in Canada from Chromatographic Specialities Inc., Brockville, ON.). Other parameters 
were set as outlined in table 2.1.  
Integration of the internal standard peak (ethanol) and ethylformate was done using 
HP 3365 Series II Chemstation (version A.03.21, Hewlett-Packard Co., 1989-1992). 
Quantitation of the ethylformate was done using the ratio of the ethylformate peak area 
to that of ethanol using standard curves (Chemistry Software for Windows®, 
ChemSW™, Inc., 1993-1998).  
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Table 2.1: Parameter values for the Gas chromatograph. 
Parameter Type Value 
Carrier Gas Helium 80 cm/sec, measured at 40º C 
Oven Isothermal 40º C 
Injector Headspace splitless 250º C 
Detector FID 300º C 
Detector gas Hydrogen 23 mL/min 
Column DB-ALC1 capillary column 30 m x 0.53 mm ID, 3.0 µm, 
 
2.3 Results 
 
Figure 2.1: Chromatographic spectrum of 1000 µL headspace of 1 mM aqueous standard 
of ethylformate. Sample was injected into a Hewlett Packard Series II 5890 
fitted with a DB-ALC1 capillary column (30 m x 0.53 mm ID, 3.0 µm) and 
Flame ionization detector using a gastight syringe. 
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Figure 2.1 is a representative chromatogram showing the internal standard (ethanol) 
eluting at 2.9 min and ethylformate at 4.5 min. A six-point linear calibration curve was 
constructed for the aqueous standards. The chromatography of these aqueous standards 
showed specificity of the method for ethylformate and its complete separation from the 
internal standard (ethanol). Spiked samples also showed chromatography consistent with 
that seen in the aqueous standards. The amount of ethanol added as an internal standard 
resulted in very high levels (final concentration 311 mM; 14.29g). Thus, any ethanol 
present in the sample would not have an effect on the quantitation. 
 
2.3.1 Linearity 
A six-point calibration curve was constructed for the low standards (Figure 2.2) and 
five-point for the high standards (Figure 2.3). The dynamic range selected was based on 
physiological levels of formate (Buttery & Chamberlain, 1988;Dorman et. al., 
1994;Jacobsen et. al., 1988;Medinsky et. al., 1997). The low standard curve calibration 
points included a blank, 0.125, 0.250, 0.500, 1.000, 2.000 and 4.000 mM. The linear 
regression equation was y = 0.0537x + 0.00075 (r = 0.9992; r² = 0.9985). The high 
standard curve calibration points included a blank, 2, 4, 10 and 20 mM. The linear 
regression equation was y = 0.00502x + -0.00034 (r² = 0.9999). 
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Figure 2.2: Standard curve of low aqueous calibrators of formic acid run on Hewlett 
Packard Series II 5890 fitted with a DB-ALC1 capillary column (30 m x 0.53 
mm ID, 3.0 µm) and Flame ionization detector using a gastight syringe. 
 
 
Figure 2.3: Standard curve of high aqueous calibrators of formic acid run on Hewlett 
Packard Series II 5890 fitted with a DB-ALC1 capillary column (30 m x 0.53 
mm ID, 3.0 µm) and Flame ionization detector using a gastight syringe. 
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2.3.2 Precision and Recovery 
The limit of detection (LOD), determined in aqueous standards, was 0.02 mM 
corresponding to imprecision (coefficient of variation, CV) of 24%. Limit of 
quantification (LOQ) was 0.026 mM (CV = 20%). The LOQ was obtained by fitting a 
curve using the equation CV = A + B*(1/mean) to estimate the relationship between 
mean and CV. Based on this model the concentration at whose upper 95% confidence 
interval for the curve has a CV of 20% is determined as the LOQ (Figure 2.4 and Table 
2.2). 
Recovery and intra-assay precision of formate in plasma was determined at two 
levels (0.125 mM and 1.000 mM). Recovery and precision at both spiked levels were 
acceptable (101-108%). Imprecision was 10.5% and 8.6% at 0.125 mM and 1 mM levels, 
respectively (Table 2.3). 
Table 2.2: Relationship between mean (replicates of 10) and coefficient of variation 
(CV) of various aqueous formate standards (mmol/L). 
 
Note: LOQ = Limit of Quantitation; Conc. = Concentration; N = Number of 
replicates; SD = Standard deviation; CV = Coefficient of variation; CI = Confidence 
interval. 
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Figure 2.4: Precision profile of various aqueous formate concentrations injected into 
Hewlett Packard Series II 5890 fitted with a DB-ALC1 capillary column (30 
m x 0.53 mm ID, 3.0 µm) and flame ionization detector using a gastight 
syringe. N = 10 per calibrator level; Coefficient of variation (CV) = [(3.357 
± 0.742 + (0.373 ± 0.007)]*(1/mean); r2 = 0.999; Std Error of Estimate = 
1.38. Limit of Quantitation (LOQ) = 0.026 mM. CI = Confidence interval. 
 
Table 2.3: Recovery and precision of aqueous spiked plasma samples. 
Sample 
Type 
Concentration 
(mmol/L) 
N 
Mean 
(mmol/L) 
SD 
CV 
(%) 
Recovery 
(%) 
1 10 1.075 0.092 8.60 108 
Plasma 
0.125 10 0.126 0.013 10.49 101 
0.125 10 0.125 0.010 8.16 100 
0.020 10 0.020 0.004 20.45 101 Aqueous 
0.010 10 0.004 0.004 90.44 43 
SD = Standard Deviation; CV = Coefficient of variation; N = number of replicates. 
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2.3.3 Clinical Samples 
Table 2.4: Summary Statistics of Plasma formate in pregnant women (n = 69). 
Statistic Value (mM) 95% Confidence Interval 
Mean 0.202 0.154 – 0.249 
Standard Deviation (SD) 0.198 0.170 – 0.238 
Range 0.011 – 0.957  
Median 0.108  
 
The results of formate analysis on 69 pregnant women are summarized in Table 2.4. 
The mean ± SD was 0.202 ± 0.198 mM. This was consistent with that found by other 
workers (Buttery & Chamberlain, 1988; Dorman et. al., 1994; Hanzlik et. al., 
2005;Medinsky et. al., 1997; Tephly et. al., 1992). Plasma formate profile with time in pigs 
(n=4) administered a bolus intravenous injection of formate (237 mg/kg, as a sodium 
formate) is shown in Figure 2.5.  
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Figure 2.5: A semilogrithmic plot of plasma formate vs time plot in young pigs (n = 4) 
administered 237 mg/kg formate by bolus injection through left jugular vein. 
Each point represents mean±SD values. 
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Table 2.5: Mean and natural log plasma formate concentrations in young pigs (n = 4) 
administered 237 mg/kg formate by bolus injection through left jugular vein. 
Time CF2 CF3 CF4 CF6 Mean formate conc. (mM) 
Ln mean conc. 
(mM) 
10 5.00 16.55 11.93 1.43 8.73 2.17 
20 3.27 11.75 9.06  8.03 2.08 
30 2.71 9.72 8.16 1.02 5.40 1.69 
45 2.19 7.78 6.08  5.35 1.68 
60 1.84 3.11 4.19  3.01 1.10 
90 1.82 4.61 3.95  3.46 1.24 
120 0.98 1.58 2.98 0.82 1.60 0.47 
180 0.73 0.65 0.68  0.69 -0.37 
240 0.35 0.32 0.60 0.61 0.47 -0.76 
480 0.35 0.29 0.35  0.33 -1.11 
 
2.4 Discussion and Conclusion 
Formate is an important compound that is present in humans, animals and plants. 
Most methods available in hospitals for diagnosis of methanol poisoning do not 
quantitate endogenous formate levels and rely instead on methanol levels. Gas 
chromatography-mass spectrometric (GC-MS) methods are able to quantitate such levels 
but require lengthy sample preparation. Such instruments are also expensive. Therefore, 
such a method is not suited for routine clinical settings. Our method combines both high 
sensitivity and simplicity accompanied by faster turnaround time. The instrument, GC-
FID, is far cheaper than GC-MS, making it a more accessible instrument for both 
hospitals and research labs. Unlike the method developed by Abolin et. al. (Abolin et. al., 
1980), this method cannot be used to monitor ethanol levels encountered in ethanol 
intoxication or levels used in the treatment of methanol poisoning. However, our method 
is approximately four times more sensitive (LOQ of 26 µM, 1.2 mg/L) than that of 
Abolin et. al. (LOQ of 109 µM, 5 mg/L). This is probably due to the fact that we used a 
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capillary column (0.53 mm ID vs 3mm in Abolin et. al.) that was much longer (30 m vs 
1.8 m in Abolin et. al.). Hence, we were able to achieve a better resolution in our peaks 
not only because of the column properties but also due to the fact that our esterification 
of formate produced ethylformate compared to methylformate in Abolin et. al. (Abolin et. 
al., 1980). Unlike ethylformate, methylformate elutes very close to methanol, thus, 
making it impossible to separate completely from the methanol peak. In fact, this was the 
reason we chose ethylformate as our esterification product. 
We have demonstrated the quantitative assay of plasma formate at various levels as 
seen in the pig and pregnant human population experiments described. The method can 
also be used in research settings as demonstrated by the data on formate disappearance in 
pigs administered formate as well as in the methanol-poisoned patient. The turnaround 
time from sample receipt to results was approximately 25 minutes.  
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CHAPTER 3 
A Simple Method for the Quantitative Analysis of Endogenous Folate 
Catabolites P-aminobenzoylglutamate(p-ABG) and Its Acetamido (ap-ABG) 
Derivative in Biological Samples by Liquid Chromatography-Tandem Mass 
Spectrometry. 
3.1 Introduction 
The amount of biologically active folate excreted by mammals is considerably less 
than that which is ingested. It has long been suggested that the major daily turnover for 
folate is via excretion of the catabolites p-aminobenzoylglutamate (p-ABG) and ap-
acetamidobenzoylglutamate (ap-ABG) (McPartlin et. al., 1992; McNulty et. al., 1993). 
Thus, the obligatory requirement of folic acid like with any other vitamin can be related 
to this catabolism. Certain conditions such as pregnancy, periods of rapid growth, during 
drug therapy regimes and in a variety of clinical conditions can increase folate catabolism 
and requirements. 
The principal function of folate coenzymes is to accept or donate one-carbon units 
in folate-requiring metabolic pathways. Cellular folates in their reduced form function 
conjugated to a polyglutamate chain, which are a mixture of unsubstituted polyglutamyl 
tetrahydrofolates and various substituted one-carbon forms of tetrahydrofolate (such as 
10-formyl, 5,10-methylene, and 5-methyl) (Figure 3.1).  
The reduced forms of the vitamin, particularly the unsubstituted dihydro and 
tetrahydro forms, are unstable chemically and are easily split between the C-9 and N-10 
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bond to yield a substituted pteridine and p-aminobenzoylglutamate, which have no 
biologic activity (Figure 3.2) (Blakley, 1969; Murphy & Scott, 1979). Substituting a carbon 
group at N-5 or N-10 decreases the tendency of the molecule to split. The substituted 
forms, however, are also susceptible to oxidative chemical rearrangements and, 
consequently, loss of activity (Blakley, 1969). The major catabolite, however, consists of 
ap-ABG whereas p-ABG exists in small amounts (McPartlin et. al., 1992;Murphy & Scott, 
1979). 
Early studies of folate catabolism in humans and laboratory animals have involved 
the administration of radiolabelled tracers, such as 14C pteroylmonoglutamate (14C 
PteGlu) and 3H pteroylmonoglutamate (3H PteGlu), and the subsequent analysis of the 
excreted catabolite in urine. McNaulty and co-workers (McNaulty, 1993) developed a 
Reverse-phase high performance liquid chromatographic method for the quantitation of 
endogenous folate catabolites independent of in vivo administration of radiolabelled 
tracers. The method, like the earlier methods, required extensive sample preparation and 
cleanup to achieve detection and quantification of the urinary catabolites. 
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Figure 3.1: The chemical structure of folic acid and the most important natural 
folates. 
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Figure 3.2: The catabolism of folic acid in the body. 
 
We have developed a novel, versatile, simple method for the detection and 
quantification of the folate catabolites p-aminobenzoylglutamate (p-ABG) and its 
acetamido derivative ap-acetamidobenzoylglutamate (ap-ABGlu) in serum, plasma and 
urine using liquid chromatography-tandem mass spectrometry (LC/MS/MS). Sample 
preparation and cleanup is achieved in one step involving precipitation with acetonitrile. 
The resulting supernatant is injected into a Biorad CAT/MET analytical column fitted on 
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Agilent 1100 liquid chromatograph coupled to a Sciex API 4000 Mass Spectrometer with 
an electrospray ionization source. Detection of the catabolites was by selective reaction 
monitoring (SRM) of the respective ions. 
 
3.2 Experimental 
3.2.1 Materials and Methods 
 
Figure 3.3: Chemical structure of 2,4,4-d3-glutamic acid. 
 
Pure p-ABG standard was obtained from Sigma-Aldrich (Oakville, ON.). Acetamido 
derivative was prepared from the p-ABG by adding 140 µL of 50% acetic acid (VWR 
Canlab, Toronto, ON.) in deionized water (Arctic Glacier, Regina, SK.) (v/v) and 20 µL 
acetic anhydride (Sigma-Aldrich, Oakville, ON., Canada) to 10 mg of pABG. The 
reaction mixture was mixed vigorously and incubated in the dark at room temperature for 
1 hour. The remaining acetic acid was allowed to evaporate under a stream of nitrogen at 
room temparature. Stock solutions of both the p-ABG and the ap-ABG were prepared in 
deionized water and contained 1.5 mM each, respectively. Aqueous serial dilutions were 
made from each of the stocks at concentrations of 100 nM, 50 nM, 10 nM and blank for 
serum and 200 µM, 100 µM, 50 µM, 10 µM and blank for urine specimens. These, 
together with the working stock solutions were stored at –20ºC. 
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d3-glutamic acid (d3-Glu) (Figure 3.3) was purchased from CDN isotopes and used 
as internal standard. A working stock solution of 1 mM was prepared in deionized water. 
HPLC grade acetonitrile (Anachemia), ammonium acetate (BDH), formic acid (Fisher 
Scientific) and, deionized water was used to prepare the HPLC mobile phase.  
 
3.2.2 Recovery experiments 
Pooled serum (from patients that are being tested for thyroid hormones) and urine 
samples (from patients being tested for drugs of abuse) were spiked with p-ABG and ap-
ABG to required concentrations (100 nM, 10 nM, and blank for serum and 100 µM, 10 
µM and blank for urine samples). Aqueous standards were prepared as described above. 2 
µL of d3-glutamic acid (1mM) was added to each 200 µL specimen as internal standard. 
Each sample was then acidified with 4 µL 6N HCl (Fisher Scientific, Ottawa, ON.) and 
vigorously vortexed. Precipitation/dilution (x3 for serum samples and x30 for urines) was 
achieved by addition of 100% acetonitrile, vortexing and spinning at 1900g for 10 
minutes. The resulting supernatant was then pipetted into a standard 96-well plate and 
placed on the Agilent 1100 well-plate autosampler. 
 
3.2.3 Analysis of clinical samples 
Blood and urine samples were collected after informed consent from a group of 5 
healthy volunteers working in our lab. Blood was collected in a serum separator tube to 
yield serum, which was immediately analysed for serum folate on the Architect automated 
immunoanalyzer (Abbott Laboratories, Abbott Park, IL.) as described in 4.2.6. The 
remainder of the sample was analysed for p-ABG and ap-ABG within the hour as 
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described above. Urine samples were collected in sterile urine containers, labelled, 
acidified to pH 3 with 6N HCl and analysed for p-ABG and ap-ABG; also within an 
hour. 
Serum samples (n = 11) collected at various collection centres, frozen within six 
hours and sent to our lab for parathyroid hormone assay were analysed for p-ABG and 
ap-ABG on the same day as PTH assay. A group of 18 serum samples from pregnant 
women was collected from a batch of serum samples sent to this lab for analysis of 
prenatal panel (rubella Ig G, syphilis, hepatitis B virus antigen and HIV antigen). Urine 
samples (24-hr urine samples stored at 4°C during collection) were collected from 
samples sent for urinary catecholamine assay in our lab (n = 19) after being acidified to 
pH 3 with 6N HCl. These urine samples were also analysed for p-ABG and ap-ABG on 
the same day as received from the urinary catecholamine bench. 
The results obtained were subjected to a modified Levene equal-variance test and 
subsequent two-tailed, two sample t-test using NCSS 2000/PASS 2000 Dawson Edition 
statistical software package (NCSS, Kaysville, UT.). 
 
3.2.4 Instrumentation 
Liquid chromatography-tandem mass spectrometry of the samples was done on an 
Agilent 1100 LC system, which includes a vacuum degasser, a binary pump, a well-plate 
auto-sampler and a heated column compartment. This system was coupled to an Applied 
Biosystems MDS Sciex API 4000 triple quadrupole tandem mass spectrometer. The 
chromatographic column consisted of a normal phase CAT/MET analytical column 
(catalog # 195-6033, Bio-Rad Laboratories, Hercules, CA.). The mobile phase 
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composition consisted of 2 mM aqueous ammonium acetate buffer with 0.1% formic 
acid (pH 3.0) and 100 % acetonitrile as the organic phase. Chromatography consisted of 
an isocratic run of 50:50 buffer to organic phase. Flow rate was set at 300 µL per minute, 
column temperature at 35ºC and an injection volume of 10 µL was used. A 15-second 
flush-port needle wash was incorporated into the procedure to prevent cross-
contamination between injections. 
Selective reaction monitoring (SRM) was done on the mass spectrometer using the 
Sciex Turbo ion spray source in positive ion mode. Resolution in quadrupole 1 (Q1) and 
quadrupole 3 (Q3) chambers were at unit mass. Other source parameters were as 
indicated in Table 3.1. The Multiple SRM mass transitions monitored were 309>162, 
309>180, both for ap-ABG and 267>120 for pABG. The dwell time for all the analytes 
was set at 500 msec. Run time for each LC injection was set at 10 minutes. Data was 
acquired and analyzed using Analyst software 1.4 (Applied Biosystems MDS Sciex). 
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Table 3.1: Turbo ion source parameters in the tandem mass spectrometer (MS/MS) for 
the analysis of p-aminobenzoylglutamate (p-ABG), ap-
acetamidobenzoylglutamate (ap-ABG) and d3-glutamic acid. 
Instrument parameter Value 
Source temperature 450ºC 
Collision associated dissociation (CAD) gas 6 p.s.i. 
Curtain gas 25 p.s.i. 
Gas source 1 & 2 (GS 1 & GS 2) 30 p.s.i. 
Ion spray voltage 5500 V 
Declustering potential (DP) for both transitions 309>162 & 309>180 (ap-
ABG) 
38 V 
Declustering potential (DP) for transition 267>120 (pABG) 35 V 
Declustering potential (DP) for transition 151>87 (d3-glutamic acid) 34 V 
Electrode potential (EP) 10 eV 
Collision energy (CE) for transition 309>162 19 eV 
Collision energy (CE) for transition 309>180 14 eV 
Collision energy (CE) for transition 267>120 12 eV 
Collision energy (CE) for transition 151>87 (d3-glutamic acid) 23 eV 
 
3.3 Results 
Figures 3.4 and 3.5 show the spectral analysis of p-ABG and ap-ABG and the 
proposed fragmentation chemistries for each as well as the internal standard d3-glutamic 
acid, d3-Glu (Figure 3.6). Mass spectral data were achieved through infusion of aqueous 
methanolic standards directly into the MS/MS. The respective ions and fragment ions 
were used to determine which selective reaction monitoring (SRM) would be monitored. 
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The chromatography of these aqueous standards showed complete separation of the 
analyte and the internal standard (d3-glutamic acid). Spiked serum and urine samples 
showed chromatography consistent with that seen in the aqueous standards (Figures 3.7-
3.10). The acetylation process of p-ABG to ap-ABG resulted in a 100% conversion 
within the 1-hour incubation period as determined by the Q1 scan data before and after 
derivatization of p-ABG (data not shown).  
 
Figure 3.4: Product ion scan (Q3) of 1 mM aqueous folate catabolite p-
aminobenzoylglutamate, p-ABG (m/z = 267) in the Q3 compartment of 
the MS/MS. 
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Figure 3.5: Product ion scan (Q3) of 1 mM aqueous folate catabolite ap-
acetamidobenzoylglutamate, ap-ABG (m/z = 309) in the Q3 
compartment of the MS/MS. 
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Figure 3.6: Proposed positive ion fragmentation of d3-glutamic acid (d3-Glu) in the 
Q3 compartment of the mass spectrometer. 
 
 
Figure 3.7: Chromatographic spectrum of p-aminobenzoylglutamate (p-ABG), ap-
acetamidobenzoylglutamate (ap-ABG) and d3-glutamic acid in 100 nM spiked 
pooled serum. 
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Figure 3.8: Chromatographic spectrum of p-aminobenzoylglutamate (p-ABG), ap-
acetamidobenzoylglutamate (ap-ABG) and d3-glutamic acid in unspiked 
pooled serum. The green and red peaks at approximately 4.9 and 5.0 min, 
respectively, are probably artifacts (unidentified co-eluting compounds). 
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Figure 3.9: Chromatographic spectrum of p-aminobenzoylglutamate (p-ABG), ap-
acetamidobenzoylglutamate (ap-ABG) and d3-glutamic acid in 100 μM 
spiked pooled urine.  
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Figure 3.10: Chromatographic spectrum of p-aminobenzoylglutamate (p-ABG), ap-
acetamidobenzoylglutamate (ap-ABG) and d3-glutamic acid in pooled 
unspiked urine. The green and red peaks at approximately 4.8 and 4.9 min, 
respectively, are probably artifacts (unidentified co-eluting compounds). 
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Figure 3.11: Standard curve of aqueous calibrators of p-aminobenzoylglutamate (pABG) 
transition (267>120). The regression of the line graph is linear through zero 
(no weighting) resulting in a regression equation of y = 0.00194x (r2 = 
0.9996). 
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Figure 3.12: Standard curve of aqueous calibrators of ap-acetamidobenzoylglutamate (ap-
ABG) transition (309>162). The regression of the line graph is linear through 
zero (no weighting) resulting in a regression equation of y = 0.0111x (r2 = 
0.9996). 
 
3.3.1 Linearity 
A four-point calibration curve for serum and five-point curve for urine were 
constructed for the standards (Figures 3.11 and 3.12). The dynamic range selected was 
based on both the limits of detection and the findings of Caudill and co-workers in which 
the baseline concentrations of the p-ABG was around 24 nM in non-pregnant women 
with folate supplementation of 450 µg/day of folic acid and around 63 nM in pregnant 
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women with 850 µg/day of folic acid supplementation (Caudill et. al., 1998). The standard 
curve calibration points included a blank, 10 nM, 50 nM and 100 nM for serum and 
blank, 10 µM, 50 µM, 100 µM and 200 µM for urine. 2 µL of 1 mM d3-Glu was added to 
200 µL of specimen as an internal standard. Linear through zero regression (no 
weighting) equations were y = 0.0111x (r2 = 0.9996) for ap-ABG 309>162 transition, y = 
0.00131x (r2 = 0.9998) for ap-ABG 309>180 transition and y = 0.00194x (r2 = 0.9996) 
for the p-ABG 267>120 transition. 
 
3.3.2 Precision and Recovery  
Intra-assay precision of ap-ABG and p-ABG for serum and urine specimens was 
determined at two levels (10 nM and 100 nM for serum and 10 µM and 100 µM for 
urine). Pooled serum and urine samples from various patients (sent for various assays to 
our reference lab) were divided into ten different aliquots and spiked with ap-ABG and 
p-ABG at the above two levels. The limit of detection (LOD) was 0.1 nM in serum 
corresponding to a signal to noise ratio of 3:1. Limit of quantification (LOQ) was 1 nM, 
which equals 33.3 femtomole (fmol) (absolute amount of sample). Table 3.2 shows the 
results of the precision and recovery assay.  
Although all transitions showed good recovery, two transitions (267>120 at 100 nM 
serum and 309>180 at 100 nM serum) had higher CV values (>20%). These high CV 
values were contributed by two samples and may also be due to an unidentified co-
eluting substance. While we did not exclude these results, we recommend that transition 
309/162 be used as a specific marker of ap-ABG.  
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Table 3.2: Recovery and precision results of p-aminobenzoylglutamate (p-ABG) and ap-
acetamidobenzoylglutamate (ap-ABG) in spiked serum and urine samples. 
Sample Analyte Transition Concentration Precision Recovery 
10 µmol/L CV = 6.06% 
n = 10 
96.90% 
 
pABG 267>120 
100 µmol/L CV = 12.66% 
n = 10 
100.35% 
10 µmol/L CV = 2.89% 
n = 10 
91.84% 309>180 
100 µmol/L CV = 4.03% 
n = 10 
95.48% 
10 µmol/L CV = 3.59% 
n = 10 
102.40% 
Urine 
ap-ABG 
309>162 
100 µmol/L CV = 3.07% 
n = 10 
102.35% 
10 nmol/L CV = 4.80% 
n = 10 
81.90% pABG 267>120 
100 nmol/L CV = 21.72% 
n = 10 
80.40% 
10 nmol/L CV = 2.54% 
n = 10 
122.80% 309>180 
100 nmol/L CV = 20.04% 
n = 10 
96.84% 
10 nmol/L CV = 2.02% 
n = 10 
88.94% 
Serum 
ap-ABG 
309>162 
100 nmol/L CV = 12.91% 
n = 10 
92.82% 
Note: CV = Coefficient of variation 
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3.3.3 Clinical Samples  
 
Figure 3.13: Box plot of serum folate levels (mean ± SD) in parathyroid hormone female 
patients (n = 11), pregnant (prenatal, n = 18) women and lab female 
volunteers (n = 5). Solid red dots represent extreme outliers. 
 
The mean age of the group for the lab volunteers was 40 years. Serum folate levels 
(mean ± SD) in this group were 35.3 ± 2.4 nM (Figure 3.13). Total serum catabolites (p-
ABG + ap-ABG) were 11.9 ± 3.1 nM with 75% of it being in the form of p-ABG and 
25% in the form of ap-ABG (Figure 3.14). Total urinary catabolites were 2.9 ± 0.9 µM 
with p-ABG consisting of 27% and 73% made up of ap-ABG. 
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Figure 3.14: Box plot of serum folate catabolites p-aminobenzoylglutamate (p-ABG) 
and ap-acetamidobenzoylglutamate (ap-ABG) (mean ± SD) in 
parathyroid hormone female patients (n = 11), pregnant (prenatal, n = 
18) women and lab female volunteers (n = 5). Solid yellow dots 
represent mild outliers. 
 
The urinary catecholamines group (n = 19) had a mean age of 50 years. Total urine 
catabolites in this group were 581.8 ± 84.5 nM. ap-ABG made up 76% while p-ABG 
consisted of 24% (Figure 3.15). The values and relative ratios of the urine catabolites seen 
here resemble that seen in the volunteers group despite the significant age difference in 
the means. 
Mean age for the PTH group (n = 11) was 55 years. Mean serum folate levels were 
27.0 ± 3.1 nM. Total serum catabolite levels in this group were 20.4 ± 7.2 nM. 37% of 
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the total folate catabolites were made up of ap-ABG. The remaining 64% was made up of 
pABG.  
Mean age for the pregnant group (n = 18) was 27 years. Serum folate levels were 
33.9 ± 5.4 nM. Total serum catabolites were 11.4 ± 2.1 nM, with ap-ABG making 17% 
and p-ABG 83% of the total catabolites.  
 
Figure 3.15: Box plot of total urinary folate catabolites p-aminobenzoylglutamate (p-
ABG) and ap-acetamidobenzoylglutamate (ap-ABG) (mean ± SD) in 
catecholamine-tested female patients (n = 19) and lab female volunteers (n 
= 5). Solid yellow dot represents mild outlier. 
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3.4 Discussion and Conclusions 
Evidence that folate catabolism proceeds by splitting of folate molecule at C9-N10 
bond was initially provided by Futterman and Silverman (Futterman & Silverman, 1957) 
who demonstrated the enzymatic reduction of folate to tetrahydrofolates followed by 
spontaneous cleavage to p-ABG and a pteridine moiety. Murphy and Scott (Murphy & 
Scott, 1979) analysed 3H-labeled compounds excreted in rat urine each day over a 10-day 
period following an intramuscular administration of [3’, 5’, 7, 9-3H] pterylglutamate. They 
found a number of pteridines and p-ABG, with the major catabolite consisting of ap-
ABG. To demonstrate the suitability of ap-ABG as an indicator of folate catabolism, 
Geoghegan and co-workers (Geoghegan et. al., 1995) showed that reverse-phase HPLC 
of radiolabeled urinary products of rats given 3H and 14C folic acid contained a variety of 
intact folate as well as products of C9-N10 scission of the folate molecule, pteridines, p-
ABG and ap-ABG. Of all the folate metabolites present in the urine, only ap-ABG 
persisted at high levels for the 10-day period of the experiment. This finding is 
corroborated by the works of Connor and co-workers (Connor et. al., 1979) and Pheasant 
and co-workers (Pheasant et. al., 1981;Caudill et. al., 1998). 
Serum folate levels in the lab volunteers (35.3 ± 5.8 nM), PTH (27.0 ± 10.4 nM) and 
prenatal (33.9 ± 22.7 nM) groups were not significantly different from each other 
(p<0.05) (Figure 3.13). These levels are consistent with levels found by the National 
Health and Nutritional Examination Survey (NHANES), 1999-2000 (Wagner, 1995). 
This study found that median serum folate concentrations for women increased from 
10.9 nM (4.8 ng/mL) to 29.5 nM (13.0 ng/mL) from 1988 - 1994 to 1999 - 2000.  
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Serum catabolite levels (Figure 3.14) in the lab volunteers, PTH and prenatal groups 
were also not significantly different form each other (p < 0.05). Serum samples collected 
for prenatal analysis are collected and shipped to the lab at 4°C. It takes up to 24-hrs for 
the sample to reach the lab. Once in the lab, the samples were analysed for p-ABG and 
ap-ABG after the designated tests (prenatal panel) were done. Thus, analysis of serum 
catabolites was done approximately 48 hours after collection and storage at 4°C. We 
believe the degradation of p-ABG and possible dilution effect of the increased blood 
volume during pregnancy could have contributed to the lower levels of serum catabolites 
seen in this group despite increased folate utilization anticipated in pregnancy (Suh et. al., 
2001;Gregory, III et. al., 2001). 
Urinary folate catabolites levels (Figure 3.15) in the lab volunteers were not 
significantly different from the catecholamine group (p< 0.05) (mean of 581.8 ± 368.4 
nM in catecholamine group vs. 2.9 ± 2.3 µM in the lab volunteers). This is probably due 
to the greater standard deviation in the catecholamine group and the fact that 
catecholamine urine samples are 24-hr urine collection. While urine samples collected 
from lab volunteers were frozen immediately upon collection, the catecholamine samples 
were stored at 4 ºC for 24-hr before being frozen. We believe that this storage condition 
would have led to loss of some catabolites. The levels seen in the lab volunteers, 
however, are similar to that seen in vivo kinetic studies of folate metabolism (Lin et. al., 
2004) and others (Caudill et. al., 1997). There was no urine sample available for the other 
groups.  
We have developed a novel, rapid test for p-ABG and ap-ABG that can be used in 
routine clinical assessment of folate catabolism. In this method, both p-ABG and ap-ABG 
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are assayed simultaneously within the same sample. The samples are acidified with a small 
amount of 6N HCl (4 µL HCl to 200 µL sample) and precipitated with acetonitrile. 
Deuterated glutamic acid (d3-Glu) is added to the samples before HCl acidification and 
acetonitrile precipitation. It is used as an internal standard because of its similarity to the 
folate catabolite molecules. Separation of the two compounds is achieved by HPLC and, 
detection by Multiple SRM of specific ions in MS/MS. Sensitivity of this method is very 
high with detection of femtomolar (fmol) amounts.  
To date, all the methods available for the analysis of folate catabolism are based on 
extensive sample clean up and use of HPLC. Not only are these methods labour intensive 
and time consuming, rendering them impractical for use in routine clinical analysis, but 
they also have limited sensitivity. The objective of this paper was to develop a routine 
method for quantitative measurement of the folate catabolites p-aminobenzoylglutamate 
(pABG) and acetamido-para--aminobenzoylglutamate (ap-ABG) in serum and urine using 
liquid chromatography-tandem mass spectrometry (LC-MS/MS). Our method provides 
ease of analysis with much higher sensitivity, specificity, and versatility regardless of the 
type of biological sample used, and faster turnaround times. 
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CHAPTER 4 
Relationship between Formate and RBC Folate Levels in Alcohol Intoxicated 
Females. 
4.1 Introduction 
Alcohol consumption is associated with a variety of health problems that include 
malnutrition, gastrointestinal and, in pregnant women, risk of having a child with Fetal 
Alcohol Spectrum Disorder (FASD) (Abel & Hannigan, 1995; Sokol et. al., 2003). 
Approximately 10% of pregnant women use alcohol, with 2% engaged in binge drinking 
(defined by the National Institute on Alcohol Abuse and Alcoholism as 4 or more drinks 
in about 2 hours) (Center for Disease Control, 2004). More than half of women who do 
not use contraceptives consume alcohol regularly with 12.4% classified as binge drinkers 
(Center for Disease Control, 2004).  
Alcohol consumption not only leads to increased ethanol but also increased 
methanol levels. This is due to methanol’s presence in all alcoholic beverages (Table 1.2) 
as a congener and a by-product of the manufacturing process that is never removed for 
fear of altering the unique taste and smell of the drink (Sprung et. al., 1988). 
Formaldehyde, a metabolite of methanol, is a much more potent reaction partner for 
tetrahydroisoquinoline (TIQ) and tetrahydro-beta-carboline (THBC) formation than 
acetaldehyde (Sprung et. al., 1988). Formic acid, another metabolite of methanol, is 
cytotoxic and capable of inducing free radical mediated damage (Dikalova et. al., 2001; 
Ellenhorn et. al., 1997; McMartin, 1977). In primates, metabolism of formate is via its 
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oxidation to CO2 (Figure 1.2), a reaction dependent on tetrahydrofolate, the metabolically 
active form of folic acid (Dorman et. al., 1994; Halsted et. al., 2002b; Larroque et. al., 1992; 
Friedmann et. al., 1954; Malorny, 1969; McMartin, 1977). During oxidation of formate a 
formyl group (CHO) is transferred to tetrahydrofolate resulting in the formation of CO2 
and H2O. Tetrahydrofolate levels depend on folic acid intake as well as on the overall 
status of the folate pathway (Figures 1.6 and 4.1). The vitamins B12 and B6 are important 
cofactors in this pathway (Bosy-Westphal et. al., 1945; Kalter, 2000; Lucock, 2000). 
Hence, any change in the folate levels is bound to have a negative effect on this pathway. 
Increased formate, decreased folate and altered one-carbon metabolism could lead to 
disastrous consequences in vulnerable groups, particularly in pregnant women where it 
could lead to the development of fetal alcohol spectrum disorder (FASD) fetus.  
In this experiment, we determined the relationship between red blood cell (RBC) 
folate and blood formate in alcohol intoxicated females. We also assessed what effect 
such a relationship would have on homocysteine, Hcy (a thrombogenic, atherogenic, 
neurotoxic non-proteinogenic amino acid whose remethylation to methionine is catalyzed 
by methionine synthase in the presence of vitamin B12), vitamin B12, and vitamin B6 
levels. 
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Figure 4.1: An overview of the folate pathway. Gly = Glycine; Ser = Serine; Hcy = 
Homocysteine; Met = Methionine; 1= Pteroylpolyglutamate synthetase; 2 = 
γ-Glutamyl hydrolase; 3 & 4 = Dihydrofolate reductase; 5 = N-Formimino-L-
glutamate:tetrahydrofolate 5-formiminotransferase (a Bifunctional enzyme in 
mammals); 6 = 10-Formyltetrahydrofolate synthetase; 7 = 10-
Formyltetrahydrofolate dehydrogenase; 8 = N-
Formylglutamate:tetrahydrofolate 5-formyltransferase; 9 = 5, 10-
Methenyltetrahydrofolate cyclohydrolase; 10 = 5- Formiminotetrahydrofolate 
cyclodeaminase; 11 = 5-Formyltetrahydrofolate cyclodehyrase; 12 = Serine 
hydroxymethyltransferase; 13 = Thymidylate synthase; 14 = 5, 10-
Methylenetetrahydrofolate reductase; 15 = Methionine synthase; 16 = 5, 10-
Methylenetetrahydrofolate dehydrogenase. 
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4.2 Experimental 
4.2.1 Chemicals  
Pure standard of formic acid (88% v/v), acetonitrile and methanol were obtained 
from Fisher Scientific (Fair Lawn, NJ.). Concentrated sulphuric acid (H2SO4) was 
purchased from J. T. Baker (Phillipsburg, NJ.) while Chromosorb 101™ packed column 
was purchased from Chromatographic specialties Inc. (Brockville, ON.). Human whole 
blood control (Biorad® #1, Bio-Rad Laboratories, Inc., Hercules, CA.) was used as the 
quality control for ethanol. 
 
4.2.2 Subject Recruitment  
Blood samples (500) collected from alcohol intoxicated patients presenting to the 
emergency room (ER) of the Royal university hospital (RUH), Saskatoon, for ethanol 
(EtOH) analysis were recruited for the study on anonymous basis. Only subjects who 
were females of less than 45 years with EtOH levels of greater than 5 mM were included 
in the study resulting in 266 samples. This group was designated as the intoxicated group. 
Apart from the EtOH already done at the hospital, methanol (MeOH), formic acid, RBC 
folate, Hcy, vitamins B12 and B6 were analyzed.  
Eighty-three (83) subjects fitting the inclusion criteria described above were recruited 
from alcohol and drug rehabilitation program center in Regina. After informed consent, 
blood samples were collected for the analysis of the same analytes as the intoxicated 
group. This group was designated as the detox group. Another group (pregnant group) of 
69 plasma samples were collected from Calgary health region on anonymous basis from 
pregnant females presenting to the prenatal clinic for a first trimester prenatal screen. 
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Ethics approval for the study was obtained from institutional ethics review board of 
the univesity of Saskatchewan, Regina Qu’Appelle health region and the Calgary Health 
Region.  
 
4.2.3 Formate Analysis  
Blood formate analysis was done using a headspace analysis technique on a gas 
chromatograph (GC) fitted with a flame ionization detector and Chromosorb 101™ 
column (GC-FID) without a headspace analyzer. A stock solution of 100 mM formic acid 
was prepared in deionized water. A seven-point linear calibration curve was constructed 
from the stock solution at 4, 2, 1, 0.5, 0.25, 0.125, and 0 mM. The samples and the 
calibrators were treated the same way as below. 
Formate present in the sample (200 µL) was methylated to methylformate by 
addition to the sample of 50 µL of MeOH in a 1 mL glass vial. Catalysis of the reaction 
was facilitated by the addition of 100 µL of concentrated H2SO4 into the reaction vial and 
sealing it. Methyl formate vapors formed were allowed to equilibrate into the headspace 
above the reaction solution in the vial for 30 minutes at room temperature before 
injecting 1 mL into the GC. Because the amount of MeOH added is in excess (250 mM) 
of what is required for methylation as well as that found in MeOH overdose, it also 
serves as an internal standard. 
 
4.2.4 Instrumentation and Data Analysis  
Analysis of methylformate was performed on a gas chromatograph fitted with a 
flame ionisation detector (Varian 3300) and a Chromosorb 101™ packed column column 
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(6’ × 1/8”, J & W Scientific, Chromatographic Specialties Inc., Brockville, ON.). Other 
parameters were set as outlined in Table 4.1.  
Table 4.1: Parameter values for analysis of methylformate in the gas 
chromatograph. 
Parameter Type Value 
Carrier Gas Nitrogen 30 mL/min 
Oven Isothermal 40ºC 
Injector Headspace to splitless 220ºC 
Detector Flame ionization detector 300ºC 
Detector gas Hydrogen 23 mL/min 
Column Chromosorb 101™ 105ºC 
 
Quantitation of the methylformate was done by plotting the peak area ratios of 
methylformate to MeOH against the calibration concentrations using Chemistry Software 
for Windows® software (ChemSW™ Inc., 1993-198). Linearity of the calibration curve 
was established in a similar manner. Linear regression analysis of standard curve 
produced r2 > 0.999. Assay limit of quantification was 0.05 mM, and intra-assay and 
inter-assay accuracy and precision had coefficient of variation values <5%. Quality 
control samples at low, medium and high concentrations were analyzed in duplicate for 
each run as acceptance criteria for the analysis.  
4.2.5 Ethanol and Methanol Analysis  
Analysis of EtOH and MeOH was done using the same instrument as for formate 
with minor modifications. The GC was fitted with Poropak Q™ packed column (6’ × 
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1/8”, J & W Scientific, Chromatographic Specialties Inc., Brockville, ON.) set at a 
temperature of 125°C (isothermal). A protein free filtrate of the sample (500 µL) diluted 
with 500 µL acetonitrile (total volume 1000 µL) was prepared by precipitation of the 
proteins using 0.3N barium hydroxide and 5% w/v zinc sulfate (500 µL, each), followed 
by centrifugation at 2600 rpm for 10 minutes. The supernatant (2 µL) was injected in to 
the GC.  
Ethanol and methanol levels were quantitated in a similar manner as formate using 
acetonitrile as internal standard. Assay limit of quantification was 0.1 mM for EtOH and 
0.03 mM for MeOH. Intra-assay and inter-assay accuracy and precision had coefficient of 
variation values <5%. Quality control samples at low, medium and high concentrations 
were analyzed in duplicate for each run as acceptance criteria for the analysis. 
 
4.2.6 Plasma and Red Blood Cell (RBC) Folate  
Plasma and RBC folates were determined by an immunoassay technique run on an 
Architect™ system (Abbott Laboratories, IL.). This assay was divided into two steps to 
determine the presence of folate in human serum, plasma, and red blood cells (RBC) 
using chemiluminescent microparticle immunoassay (CMIA) technology with flexible 
assay protocols, referred to as chemiflex. Two pre-treatment steps mediated the release of 
folate from endogenous folate binding protein. In pre-treatment step 1, sample and pre-
treatment reagent 2 (Dithiothreitol or DTT) were aspirated and dispensed into a reaction 
vessel (RV). In pre-treatment step 2, an aliquot of sample/pre-treatment reagent 2 
mixture was aspirated and dispensed into a second RV. Pre-treatment reagent 1 
(potassium hydroxide or KOH) was then added. An aliquot of the pretreated sample was 
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transferred into a third RV, followed by the addition of folate binding protein (FBV) 
coated paramagnetic microparticles and assay specific diluent. Folate present in the 
sample was bound to the FBV coated microparticles. After washing, pteroic acid-
acridinium labeled conjugate was added and bound by unoccupied sites of the FBV 
coated microparticles. Pre-trigger and trigger solutions were then added to the reaction 
mixture; the resulting chemiluminescent reaction was measured as relative light units 
(RLUs). An inverse relationship existed between the amount of folate in the sample and 
the RLUs detected by the Architect optical system. 
 
4.2.7 Homocysteine (Hcy)  
Plasma homocysteine was determined by an immunoassay technique run on an 
Immulite® 2000 system (DPC Los Angeles, CA). In this assay, the sample was pretreated 
with S-adenosyl-L-homocysteine (SAH) hydrolase and Dithiothreitol (DTT) by 
incubating the mixture for 30 minutes in a tube containing no bead. After the incubation 
period, the treated sample was then transferred to a second tube containing a SAH-
coated polystyrene bead and an alkaline phosphatase-labeled antibody specific for SAH 
and incubated for another 30 minutes. During this incubation period, the converted SAH 
from the pretreated sample competed with immobilized SAH for binding to the 
antibody-labeled enzyme. Unbound enzyme was removed by centrifugal wash. The 
reaction mixture was then analyzed in the immulite® 2000 Analyzer. 
4.2.1 Vitamins B6 & B12  
Plasma vitamin B-6 (PLP) levels were analyzed using HPLC system utilizing the 
method developed by Deitrick and co-workers (Deitrick et. al., 2001). Briefly, 500 µL of 
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plasma was deproteinated with 500 µL 0.8 M perchloric acid. The mixture was vortexed 
vigorously for 1 minute and centrifuged at 1900g for 5 minutes. The supernatant (50 µL) 
was injected into an HPLC fitted with a Purospher C18 column and a diode array 
detector. Mobile phase A was 0.1 mol/L potassium dihydrogen phosphate buffer (pH = 
3.5) and, mobile phase B (the column clean-up phase) was 100% acetonitrile. For 
quantification, the peak area from each sample was compared with standard calibration 
curve of PLP. 
Plasma vitamin B12 was analyzed using immunoassay technique run on an 
Architect™ system (Abbott Laboratories, IL.). This system utilizes a chemiluminescent 
microparticle immunoassay (CMIA) technology with flexible assay protocols. The 
pretreated sample was mixed with a diluent and intrinsic factor coated with paramagnetic 
microparticles. Vitamin B12 present in the sample was bound to the intrinsic factor. The 
complex is washed and then had B12 acridium-labeled conjugate added to it. After 
addition of pre-trigger and trigger solution to the final mixture, a chemiluminescent 
reaction took place, which was measured as relative light units (RLUs). An inverse 
relationship existed between amount of vitamin B12 present in the sample and RLUs 
detected by the ARCHITECT i2000 optical system. 
 
4.2.9 Data Analysis  
Mean±SE values of each analyte were calculated for each group. Two-sample t-test 
was done to compare means between the two groups using NCSS 2007 software (NCSS, 
Kaysville, UT.).  
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4.3 Results 
Table 4.2: Results of various analytes in alcohol intoxicated and detox rehabilitation 
females.  
Intoxicated  
(n = 266) 
Detox  
(n = 83) 
Parameter Result (mean ± SE) 
p-
value Conclusion
Age (yrs) 34 ± 1 28 ± 1 0.001 H1 
Ethanol (mM) 38.84 ± 1.77 0.11 ± 0.00 0.000 H1 
Methanol (mM) 0.13 ± 0.01 0.04 ± 0.00 0.003 H1 
Blood formate (mM) 0.10 ± 0.00 0.10 ± 0.01 1.000 H0 
RBC folate (nM) 575 ± 23 643 ± 30 0.151 H0 
Hcy (µM) 7.08 ± 0.23 8.23 ± 0.32 0.012 H1 
Vit B12 (pM) 287 ± 15 221 ± 10 0.000 H1 
Vit B6 (nM) 43.97 ± 3.26 20.13 ± 2.01 0.000 H1 
Note: H0 = no statistical difference between means at p=0.05; H1 = the means are 
statistically different at p=0.05; SE = Standard Error. 
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Table 4.3: Results of various analytes in pregnant females (n = 69). 
Parameter Result (mean ± SE) 
Plasma formate (mM) 0.202 ± 0.02 
Plasma folate (nM) 40.53 ± 3.16 
Homocysteine (µM) 5.57 ± 0.24 
Vitamin B12 (pM) 395.00 ± 36.00 
Note: SE = Standard Error 
 
The results of the analysis of the intoxicated, detox and pregnant groups are 
summarized in Tables 4.2 and 4.3. Mean age (mean ± SE) was higher in the intoxicated 
group (34 ± 1 years vs 28 ± 1 years in the detox group, p = 0.001). Ethanol and 
methanol levels were also higher in the intoxicated group (38.84 ± 1.77 mM vs 0.11 ± 
0.00 mM, p = 0.000 and 0.13 ± 0.01 vs 0.04 ± 0.00, p = 0.003, respectively). Plasma 
formate in the pregnant group (Table 4.2) was 0.173 ± 0.02 mM. Blood formate and red 
cell formate levels were not statistically different between the intoxicated and detox 
groups. However, Hcy levels were lowest in the pregnant group (5.57 ± 0.24 µM). Levels 
in the intoxicated and detox groups were 27% (7.08 ± 0.23 µM, p = 0.000) and 48% (8.23 
± 0.32 µM, p = 0.000) higher, respectively. Vitamin B12 levels were highest in the 
pregnant group (395 ± 36 pM) while the detox group had the lowest (44% lower; 395 ± 
36 pM, p = 0.000). Vitamin B12 levels in the intoxicated group were 27% lower (287 ± 
13 pM, p = 0.005). Vitamin B6 levels in the detox group were 54% lower compared to 
the intoxicated group (20.13 ± 2.01 µM vs 43.97 ± 3.26 µM, p = 0.000). 
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Figure 4.2: Linear regression plot of natural logarithmic of blood formate vs 
RBC folate levels in alcohol intoxicated females (Age < 45 years, n = 
260). Correlation (r)= 0.0899. 
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Figure 4.3: Linear regression plot of natural logarithmic of blood formate vs RBC 
folate levels sober females in Detox program (Age < 45 years, n = 80). 
Correlation (r) = 0.2382. 
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Figure 4.4: Linear regression plot of natural logarithmic of plasma formate vs 
plasma folate levels sober pregnant females (n = 67). Correlation (r) = 
-0.4989. 
 
Linear regression analysis of natural log of blood formate against RBC folate in the 
intoxicated group (Figure 4.2) produced a correlation coefficient of 0.0899. A similar 
correlation for the detox group (Figure 4.3) produced a correlation of 0.2382. The 
correlation of natural log of plasma formate against plasma folate in the pregnant group 
(Figure 4.4) produced correlation of -0.4989.  
 
4.4 Discussion and Conclusion  
Formate is a toxic compound that is also normally present at low levels in humans, 
animals and plants. In the body it arises from intermediary metabolism of histidine and 
tryptophan. The major exogenous source of formate is through ingestion of MeOH and 
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MeOH-containing drinks. The toxicity of formate is well documented and includes 
metabolic acidosis, free radical damage and cytotoxicity (Clay et. al., 1975; Dikalova et. al., 
2001; Friedmann et. al., 1954; Hantson et. al., 2005; Jacobsen et. al., 1988; Jacobsen et. al., 
1982; Kerns et. al., 2002; McMartin, 1977). Folic acid is an essential vitamin and cofactor 
required for a wide range of biochemical pathways involving one carbon metabolism 
(Wagner, 1995) including the metabolism of formate to CO2 and H2O during 
methanol/formic acid intoxication (Makar et. al., 1990; Medinsky et. al., 1997). Thus, body 
folate requirement is directly related to the amount of these biological processes 
(McPartlin et. al., 1992; McNulty et. al., 1993). Thus, in the absence of adequate folic acid 
supplementation one would expect folate levels to decrease as formate levels rise and vice 
versa. 
In this study human female subjects of child-bearing age were recruited because of the 
susceptibility of developing fetus to formate toxicity. These groups were also chosen to 
represent alcohol intoxication state (intoxicated females), malnutrition state (as represented 
in recovering alcoholics in the detox program) and, pregnancy state (represented by the 
prenatal clinic recruits). As expected, we observed an inverse (negative) relationship 
between plasma formate and folate levels (Correlation = -0.4989; Figures 4.4).  No 
meaningful relationship, however, was observed for both the intoxicated and detox groups. 
It is important to note that formate levels observed in the intoxicated group was not 
elevated and were consistent with those seen in non-methanol intoxicated individuals 
(Ellenhorn et. al., 1997; McMartin et. al., 1980; Osterloh et. al., 1986; Sejersted et. al., 1983; 
Yip & Jacobsen, 2003). This is probably due to sampling issues. The blood samples from 
these subjects were collected as part of their treatment protocol as they would have 
  103
presented to the hospital emergency room. Thus, significant time might not have elapsed 
for methanol to be metabolized to formate. This is supported by the elevated ethanol and 
methanol levels in this group compared to the detox group suggesting that blood was 
drawn before significant methanol was metabolized.   
Low formate levels in the intoxicated group could also be explained by the fact that 
these individuals might have consumed grain/fruit based alcoholic beverage. Such 
alcoholic beverages contain levels of B-vitamin that meet, and in some cases exceed, the 
recommended daily allowance (RDA), Table 4.4 (Kellner & Cejka, 1999; Walker & 
Baxter, 2000). Because of the proximity of the recruiting institution (RUH) to the 
university, it is plausible that most of these subjects were university students on a binge-
drinking spree. Most of the other subjects might also have been binge drinkers as 
opposed to chronic alcoholics. As a result they would have been inadvertently 
supplementing with B-vitamins.  
 
Table 4.4: Amount of B-vitamins present in 1 L of Pilsner Beer (Pilsner Urquel).  
Vitamin Level (µg) RDA (µg/day)* 
Folate 400 - 600 400 
B6 70 - 1700 1300 
B12  3 - 140 2.4 
Note: RDA=Recommended Daily Allowance; *values from Dietary Reference 
Intakes by Institute of Medicine, 1998, National Academy Press, 
Washington. 
 
The argument that the intoxicated group could be mostly made up of binge beer 
drinkers is supported by the observation of lower Hcy and higher vitamin s B12 and B6 
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levels in this group compared to the detox group, an observation consistent with that of 
Beulens and coworkers (Beulens et. al., 2005) in which they observed increased plasma 
vitamins B6 (11%) and B12 in non-alcoholic volunteers consuming alcoholic beer over a 
3 week period. Lower vitamins B6 and 12 levels in the detox group would suggest that 
this group is primarily made up of chronic alcoholics, who often suffer from 
micronutrient deficiency, especially B-vitamins (Cravo & Camilo, 2000).  
We, therefore, conclude from this study that a negative (inverse) relationship might 
exist between plasma formate and folate levels. However, there is insufficient evidence to 
make any meaningful conclusion in blood.  
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CHAPTER 5 
Formate Pharmacokinetics During Formate Insult in Folate Deficient Young 
Swine. 
5.1 Introduction 
Formic acid and its conjugate base formate are essential endogenous one-carbon 
metabolites in most living organisms participating in vital one-carbon pool of 
intermediary metabolism. It is produced in the body as a result of catabolism of several 
amino acids including serine, glycine, histidine and tryptophan, as well as by the recycling 
of methylthioadenosine from the polyamine biosynthesis pathway (Cook et. al., 2001; Fu 
et. al., 2001) through the oxidation of formaldehyde generated during cytochrome P450-
catalyzed N- and O-demethylation reactions (Keefer et. al., 1987). Formate is also 
produced during the hydrolysis of certain prodrugs containing acyloxymethyl substituents 
as protecting groups, such as Fosphenytoin and its analogs (Stella, 1996). Exogenous 
sources of formate include methanol containing alcoholic beverages, fragrances, roasted 
coffee, food flavours (especially fruit and honey mixtures) and industrial products such as 
decalcifiers, acidulating agents in textile dying and finishing, and mold inhibitors in grain 
and silage. Formic acid, a metabolite of methanol (MeOH), is responsible for the toxicity 
observed in methanol poisoning (Figure 1.2) (Barceloux et. al., 2002; Dorman et. al., 1994; 
Sejersted et. al., 1983). During methanol intoxication methanol is first metabolized by 
alcohol dehydrogenase (ADH) to formaldehyde and thence to formic acid by aldehyde 
dehydrogenase (Figure 1.2). Excess formate production may then lead to formate 
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accumulation and toxicity such as optic nerve damage, increased anion gap and metabolic 
acidosis (Medinsky et. al., 1997; Smith & Taylor, 1982). Urinary excretion of formic acid is 
low (about 2%-7%) (Friedmann et. al., 1954; Malorny, 1969; Sperling et. al., 1953).  
The vitamin folic acid plays a major coenzymatic role in one carbon metabolism and 
is also a critical cofactor in the elimination of formic acid. Folate coenzymes function to 
accept or donate one-carbon units in folate-requiring metabolic pathways (Wagner, 1995). 
During formate metabolism folate coenzymes transfer a formyl group (CHO) to 
tetrahydrofolate resulting in the formation of CO2 and H2O (Medinsky et. al., 1997; 
Makar et. al., 1990). Thus, adequate tetrahydrofolate levels are important for efficient 
formate metabolism. The importance of maintaining optimal folate levels in reducing the 
detrimental effects of formate in the body cannot be ignored given the ubiquitous nature 
of methanol and formate, formate’s role in free radical damage (Dikalova et. al., 2001) and 
the dependency of its metabolism on folate status. 
Species differences exist in the metabolism of formate. This is due to differences in 
the activities of formyltetrahydrofolate synthetase, the enzyme catalyzing the transfer of 
CHO group to tetrahydrofolate, methylenetetrahydrofolate dehydrogenase, which 
catalyzes the removal of H+ from 5, 10-methylenetetrahydrofolate to form 5, 10-
methenyltetrahydrofolate, and the tetrahydrofolate substrate (Black et. al., 1985; Johlin et. 
al., 1987; Johlin et. al., 1989). Species susceptible to methanol/formate poisoning have 
lower hepatic tetrahydrofolate levels and thus slower formate metabolism than resistant 
species such as rats. Pigs have the lowest levels (3.3 ± 1.1 nmol/g, mean ± SE) compared 
to rats (11.4 ± 0.8 nmol/g, mean ± SE) (Tephly et. al., 1992). Hence, mice and rats have 
the highest rate of formate metabolism and are less susceptible to formate toxicity while 
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humans and pigs tend to be more susceptible. This suggests that pigs may be an 
appropriate model system for investigations into the effects of formate toxicity and its 
relationship to folate status. The purpose of this experiment was to determine the 
influence of folate deficiency on the pharmacokinetics of exogenously administered 
formate in a pig model.  
 
5.2 Experimental 
5.2.1 Chemicals  
Pure formic acid standard (88% v/v) was obtained from Fisher Scientific (Fair Lawn, 
NJ, USA) and sodium formate from Sigma-Aldrich (Oakville, ON.). Normal saline was 
obtained from Fluka (Oakville, ON.). Sulphuric acid and anhydrous ethyl alcohol were 
purchased from J. T. Baker (Phillipsburg, NJ.) and Commercial Alcohols Inc. (Brampton, 
ON.), respectively. Gas tight syringes (Hamilton 1.25 mL; 22/2”/2) were purchased from 
Hamilton Company (Reno, NV.). All other chemicals used were analytical grade.  
 
5.2.2 Animals and Husbandry 
The diets consisted of a semi-purified diet formulated to meet the nutrient 
requirements of the 5 - 20-kg pig. The basal diet (folate control diet, FFC) consisted of 
48.6% corn starch, 20% lactose, 15% casein, 5% corn oil, 5% cellulose, 2.2% 
monocalcium phosphate, 1.5% limestone, 0.5% salt, and 0.2% cystine and a 
vitamin/mineral premix that provided 150% of the nutrient requirements of swine for 
micronutrients (National Research Council, 1998). Folic acid was provided at 0.6 mg/kg. 
The composition of folate deficient diet (FFD) was the same as that of FFC diet except 
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folic acid was eliminated. Additionally, 1% succinylsulfathiazole was added to both diets 
as an antibiotic to prevent the synthesis and absorption of folate produced by commensal 
microorganisms in the gastrointestinal tract. Diets were offered to piglets in the form of 
powder for 4 weeks before administration of formate. Folate deficiency was confirmed 
with plasma level determinations (<30 nmol/L).  
Twelve pigs (all male, ~5 kg; Cotswold Canada Ltd.), weaned at 18 days of age, were 
randomly assigned to 1 of 2 treatment groups (n = 6/group). Pigs receiving the FFC diet 
were matched (by body weight) to corresponding folate-deficient pigs (FFD) and 
received equivalent diet allotment using a pair-feeding protocol. Feed intake was 
measured daily. Folate status was monitored weekly for 6 weeks. When plasma folate 
concentrations had reached a nadir (<30 nmol/L) (after 6 weeks), the pigs were subjected 
to the formate experiments. 
Pigs were group housed on raised, plastic-coated mesh flooring (4 pigs/pen), in an 
environmentally controlled room with continuous lighting. Temperature was initially set 
at 30°C, and gradually reduced to 25°C over the 6-week experimental period. Each pen 
was equipped with a self-feeder and a water nipple, to permit ad libitum intake of feed and 
water. Fresh feed was offered daily and body weight was measured weekly. The study was 
approved by the institutional committee on animal care and conducted in accordance 
with the Canadian Council of Animal Care guidelines (Olfert et. al., 1993). 
 
5.2.3 Formate Formulation and Administration 
Four pigs (31-38 kg) in each group were administered sodium formate (351 mg/kg; 
237 mg/kg formate base) via a surgically inserted catheter in the left jugular vein. The 
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remaining two pigs in each group were administered sterile saline via the same vein. 
Formate infusion over a 10 min period (109-133 mL solution in each animal depending 
on the weight of the animal) was carried out according to good practice guidelines (Diehl 
et. al., 2001). Saline infusion (111-130 mL depending on body weight) was also performed 
in a similar manner. Sodium formate was prepared in normal saline and sterilized by 
autoclaving (AMSCO Isothermal® operated at 17.1-19.5 p.s.i. at 121ºC for 15 minutes) 
before use. Blood samples (~10 mL) were collected using sterile syringes coated with 
sodium heparin before and at 10, 20, 30, 45, 60, 90, 120, 180, 240 and 480 min post 
infusion. For plasma, samples were kept on ice during the collection period and 
centrifuged soon after sample collection was over for that period to remove the cells. The 
resultant plasma was then stored at -80ºC until analysis. For RBC folate whole blood 
samples were stored at 4ºC till analysis. 
 
5.2.4 Formate Analysis 
Formate analysis was done as described earlier in Sections 2.2.2 to 2.2.4.  
 
 
 
 
 
5.3 Results 
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Figure 5.1: Box plot of Log mean plasma formate levels at the end of infusion in 
male pigs (n = 12) after infusion of 351 mg/kg sodium formate (237 
mg/kg formate; n= 4/group) and physiological saline (111 – 130 mL; n 
= 2/group). Infusion was done over 10 min. Formate_FFD = Formate 
infused folate deficient group; Formate_FFC = Formate infused folate 
control group; Saline_FFD = Saline infused folate deficient group; 
Saline_FFC = Saline infused folate control group. 
 
To reach folate deficiency status, the designated group (FFD) of pigs was fed a folate 
deficient diet for six weeks. Folate deficiency was successfully induced in this group at the 
end of 6 weeks as confirmed by plasma measurements (26 ± 5 nmol/L, Mean ± SE), 
which were at nadir (<30 nmol/L) and statistically different from the folate control diet 
fed pigs (p = 0.007). To determine whether folate deficiency altered formate 
pharmacokinetics, pigs were administered formate or saline via a short intravenous 
infusion. At the end of the infusion, plasma formate levels rose from a baseline value of 
0.16 ± 0.01 mM (mean ± SE), in folate deficiency (FFD) and 0.12 ± 0.05 mM in folate 
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control (FFC), to a maximum concentration (Cend-inf) of 9.63 ± 0.57 mM and 10.04 ± 
0.71 mM, respectively. Formate levels in saline administered animals did not rise 
significantly (Figure 5.1). Folate deficient diet pigs (FFD) accumulated more formate than 
FCC pigs, as indicated by the ~2.5-fold higher AUC values of FFD pigs relative to the 
FFC pigs (Figure 5.2 and Table 5.1). The plot of formate concentration as a function of 
time indicated first order elimination kinetics for both folate replete and deficient groups 
(Figure 5.2), but the slope of the log-linear terminal phase was much shallower in folate 
deficient pigs (FFD) (Figures 5.2). The half-life (t1/2) of formate in FFD pigs was 
approximately 2.5-fold higher relative to the FFC pigs. Systemic clearance of formate was 
about 44% lower in FFD than FFC pigs, but volume of distribution (VSS) remained 
approximately 18 L in both groups.  
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Figure 5.2: Semilogrithmic plot of plasma formate (mean ± SE) concentration 
(mM) vs time of folate deficient (FFD) and folate control (FFC) male 
pigs (n = 4; 31 - 38 kg). Animals were given a short intravenous 
infusion (~10 min) via the left jugular vein with 351 mg/kg sodium 
formate (237 mg/kg formate). 
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Table 5.1: Pharmacokinetic parameter estimates of formate in folate deficient (FFD) & 
folate control (FFC) male pigs.  
Parameter Units FFD ± SE 
CV 
(%) 
FFC ± SE 
CV 
(%) 
p-
value 
Conclusion 
Cend-inf mM 9.63 ± 0.57 5.87 10.04 ± 0.71 7.04 0.668 H0 
Cend-inf Mg/L 443 ± 26 5.88 462 ± 32 7.04 0.661 H0 
AUC g min L-1 72.37 ± 8.29 11.4 30.08 ± 2.58 8.58 0.003 H1 
K min-1 0.0061 ± 0.0009 14.9 0.0154 ± 0.0020 12.88 0.005 H1 
t1/2 min 113 ± 17 14.9 45 ± 6 12.85 0.009 H1 
MRT min 163 ± 24 14.9 65 ± 8 12.8 0.008 H1 
ClS L min-1 0.12 ± 0.01 11.5 0.27 ± 0.02 8.59 0.001 H1 
VSS L 18.84 ± 1.05 5.89 17.21 ± 1.35 7.04 0.377 H0 
Note: Pigs (31-38 kg) were administered 351 mg/kg sodium formate (237 mg/kg 
formate; n=4/group) via intravenous infusion (10 min) into the left jugular vein. 
Blood samples were collected over an 8-hour period. Values with the exception of 
CV (%) represent mean ± standard error (SE). CV = Coefficient of variation; H0 = 
No statistical difference between means at p=0.05; H1 = The means are statistically 
different at p = 0.05; AUC = Area under the curve; K = Elimination constant; t1/2 
= Elimination half-life; Cend-inf = Concentration at end of infusion; ClS = 
Systemic clearance; MRT = Mean residence time; VSS = Volume of distribution 
under steady state 
 
5.4 Discussion and Conclusions 
Formate is a toxic compound that is normally present at low levels in humans, 
animals and plants. Endogenous formate arises from intermediary metabolism through 
such metabolic pathways as histidine and tryptophan degradation. Exogenous sources of 
formate include methanol containing alcoholic beverages, fragrances, roasted coffee, food 
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flavours (especially fruit and honey mixtures) and industrial products such as decalcifiers, 
acidulating agents in textile dying and finishing and, mold inhibitors in grain and silage. 
Folic acid, an essential vitamin and building block of tetrahydrofolate, is required in the 
metabolism of formate. Thus, efficient formate metabolism depends upon the activities 
of formyltetrahydrofolate synthetase and methylenetetrahydrofolate dehydrogenase, 
enzymes involved in folate metabolism and tetrahydrofolate levels (Black et. al., 1985; 
Johlin et. al., 1987; Johlin et. al., 1989). Species and individual differences exist in 
tetrahydrofolate levels. Consequently, variable rates of formate metabolism are 
encountered across species and individuals (Table 5.2). Thus, mice and rats have the 
highest rate of formate metabolism and are less susceptible to formate toxicity while 
humans and pigs tend to be more susceptible. Consequently, folate status may have a 
marked impact on formate levels and predisposition to formate toxicity.  
Table 5.2: Levels of hepatic folate intermediates in various species and subspecies.  
Species/Subspecies concentration (nmol/g) 
Folate Intermediate 
Mouse1 Rat1 Monkey1 Human1
Outbreed 
swine2 
Micropigs3
Yucatan 
Mininpigs4
Tetrahydrofolate 42.9±1.2 11.4±0.8 7.4±0.8 6.5±0.3 3.3±1.1 1.6±0.2  
5-
Methyltetrahydrofolate 
11.6±0.4 9.3±0.6 7.6±0.6 6.0±0.7 1.0±0.2 5.4±0.5  
Formyltetrahydrofolate 6.4±0.6 4.6±1.3 10.5±0.8 3.3±0.5 0.7±0.1 1.3±0.2  
Total 60.9±2.1 25.3±0.9 25.5±1.2 15.8±0.8 5.1±1.2 8.2±0.6 17.5±2.2 
Note: Values represent mean ± Standard Error (SE). 1Data from Johlin et. al., 1987; 2Data 
from Makar et. al., 1990; 3Data from Tephly et. al., 1992; 4Data from Dorman et. al., 
1993. 
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In the present study, formate levels increased ~70-fold following formate 
administration relative to the saline controls (Figure 5.2). The amount of formate 
administered (237 mg formate/kg) and the resultant formate levels have not been 
associated with overt metabolic crisis (Makar et. al., 1990; Tephly et. al., 1992; Dorman et. 
al., 1993; Jacobsen & McMartin, 1986; Sophia Dyer, 1998) and no physical distress was 
observed in our animals during the experiment. This is consistent with Dorman and co-
workers (Dorman et. al., 1993), Makar (Makar et. al., 1990), and Tephly (Tephly et. al., 
1992) who reported only minimum metabolic acidosis or bicarbonate depletion following 
administered doses of 425 mg/kg or 500mg/kg sodium formate (338 mg/kg formate).  
Folate deficiency resulted in a significant decrease (55%) in the systemic clearance of 
formate but had no affect on the volume of distribution (~18 L; 0.53L/kg, p=0.377). 
Hence, the significantly lower elimination rate constant (2.5-fold) and longer half-life 
(2.5-fold) in folate deficient pigs was due to changes in systemic clearance alone. This is 
consistent with folate’s critical role in formate metabolism. Consequently, folate 
deficiency state results in higher formate exposure as observed by the 2.5-fold higher 
AUC and MRT values in FFD pigs relative to FFC pigs (72.37 ± 8.29 g min L-1 vs 30.08 
± 2.58 g min L-1 and 163 ± 24 min vs 65 ± 8 min, respectively).  
Increased formate exposure can lead to metabolic acidosis, free radical damage and 
neurotoxicity (Medinsky et. al., 1997; Hantson et. al., 2005; Jacobsen et. al., 1988; Jacobsen 
& McMartin, 1986; McMartin, 1977; McMartin et. al., 1980). Formaldehyde, a highly 
reactive intermediary metabolite of methanol and precursor of formic acid, can combine 
with a variety of cellular constituents forming relatively stable adducts (Medinsky et. al., 
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1997). For example, formaldehyde combines with glutathione to form S-
formylglutathione. This may significantly alter glutathione levels leading to reduced 
antioxidant capacity. The formic acid molecule dissociates completely at physiological pH 
into its conjugate base, formate, and a hydrogen ion. Formate distributes freely into total 
body water and is found in blood and CSF. The increased amounts of hydrogen ions 
formed as a result of the dissociation eventually overwhelm the normal acid-base balance 
of the body resulting in acidosis. Formate is also neurotoxic leading to edema and 
atrophy of the optic nerve (resulting in permanent vision loss). Damage to the putamen 
of the basal ganglia of the brain (the area that controls gross intentional motor activities 
that are normally performed unconsciously) is often seen in autopsies of victims of 
methanol poisoning. These adverse effects are reportedly associated with prolonged 
blood formate elevation (> 7 to 10 mM) of greater than 24 hours. Although endogenous 
levels of formate are low, ranging form 0.12 to 0.28 mM (Buttery & Chamberlain, 1988), 
it is conceivable to obtain much higher levels due to exposure from various sources (as a 
result of extensive use of formate in industry) in a folate deficiency state. Other 
conditions such as pregnancy, disease, malnutrition and convalescence can also aggravate 
folate deficiency and formate accumulation. 
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Table 5.3: Formate elimination half-life in various species.  
Animal Minipig1 
Outbreed 
swine2 
Micropig2 Human4,5 Rat6 Monkey7
Formate t1/2 
(min) 
50 - 112 87 ± 18 74.1 ± 6 69 - 120 12 - 23 31 - 51 
Note: 1, 4, 5, 6 and 7 values represent ranges while 2 values represent Mean ± Standard Error 
(SE). 1Data from Dorman et. al., 1993; 2Data from Makar et. al., 1990; 3Data from 
Tephly et. al., 1992; 4Data from McMartin et. al., 1980; 5Data from Hanzlik et. al., 
2005; 6Data from Clay et. al., 1975; 7Data from McMartin, 1977. 
 
Our observations of formate kinetics as demonstrated by t1/2, in normal pigs seem to 
support that of other workers (Table 5.3) with the exception of Vss. The Vss obtained of 
approximately 18 L (0.53 L/kg) is much lower than that observed by others. For 
example, Hanzlik (Hanzlik et. al., 2005) found the Vss of formate in human females given 
an oral dose of 3900 mg calcium formate to be 2.36 L/kg. By extrapolating the kinetic 
plots (lnC versus t) of Clay et. al. (Clay et. al., 1975) to time 0 and dividing by the dose, 
Hanzlik and colleagues calculated the dose-independent Vss of formate as 2.25 L/kg. 
They also obtained a Vss of 2.58 L/kg by similar extrapolation of the kinetic plot of Eells 
et. al. (Eells et. al., 1981). This difference between our value and that of others is probably 
due to the fact that Hanzlik et. al. (Hanzlik et. al., 2005) and Eells et. al. (Eells et. al., 1981) 
obtained Vss based on oral and intraperitoneal administration of formate. Thus, such an 
estimate of Vss is confounded by formate bioavailability (i.e. the estimate is actually 
Vd/F). Also, the lack of the formate bioavailability in their work and in the literature 
leaves much speculation on how our value for Vss compares to others. Another possible 
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reason for this difference may be due to our short-term infusion (~10 min). As a result, 
there may be certain error associated with a Vss derived in such a manner. The i.v. 
infusion over such a time (~10 min) was necessary to address concerns of formate 
toxicity that might arise in the folate deficiency animals (351 mg/kg sodium formate 
administered in a 109-133 mL solution to each animal depending on the weight) as well 
as to comply with safe infusion guidelines for such animals (Diehl et. al., 2001).  
We have demonstrated that folate deficiency significantly reduces systemic formate 
clearance resulting in increased risk of formate toxicity in folate deficient pigs. The 
experimental model described in this study (of folate deficient pig) can serve as the basis 
of further research on modulation of effects of formate toxicity in folate deficiency in 
humans. Further research is needed to elucidate the effects (subclinical and clinical) of 
formate during folate deficiency in tissues and on biochemical parameters, and how this 
relates to disease manifestations. 
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CHAPTER 6 
Folate Utilization During Formate Insult in Folate Deficient Pigs. 
6.1 Introduction 
Folic acid (Figure 3.2) is an antioxidant and a vitamin that plays a major coenzymatic 
role in one carbon metabolism. The principal function of folate coenzymes is to accept or 
donate one-carbon units in folate-requiring metabolic pathways (Wagner, 1995), e.g., 
DNA methylation. The folate molecule that acts as an acceptor of carbon in the one-
carbon cycle is in the polyglutamyl form of tetrahydrofolate (THF) (Wagner, 1995). 
The amount of biologically active folate excreted by mammals is considerably less 
than the amount obtained from dietary sources. The major daily turnover for folate is via 
excretion of the folate catabolites p-aminobenzoylglutamate, p-ABG, and ap-
acetamidobenzoylglutamate, ap-ABG (McPartlin et. al., 1992; McNulty et. al., 1993) 
(Figure 3.2). Thus, the obligatory requirement of folic acid, like with any other vitamin, 
can be related to this catabolism. Certain conditions, such as pregnancy, periods of rapid 
growth, during drug therapy regimes and in a variety of disease conditions, can increase 
folate catabolism and, hence, its requirements. 
The overall status of the one carbon pathway is also dependant on the levels of 
methionine and vitamins B6 and B12 (Figure 1.6) (Bailey & Gregory, III, 1999; Barak et. 
al., 1991; Barber et. al., 1999; Halsted et. al., 2002a; Lucock, 2000; Scott et. al., 1993). In 
situations of poor folate status, S-adenosylhomocysteine (SAH) concentration increases 
due to the impairment of methyl group synthesis and homocysteine remethylation. 
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Inhibition by resulting product (SAH) suppresses many of the SAM-dependent 
methyltransferase reactions (Selhub & Miller, 1992). This illustrates the far-reaching 
effects of impaired one-carbon metabolism during such a nutritional deficiency. 
Folic acid is also a cofactor in the elimination of formic acid. Formic acid and its 
conjugate base, formate, are essential endogenous one-carbon metabolites in most living 
organisms participating in vital one-carbon pool of intermediary metabolism (Cook et. al., 
2001; Fu et. al., 2001). However, formate is also a metabolite of methanol (MeOH) and is 
responsible for the toxicity observed in methanol poisoning (Barceloux et. al., 2002; 
Dorman et. al., 1994;Sejersted et. al., 1983) (Figure 1.2). Methanol is first metabolized to 
formaldehyde by alcohol dehydrogense, which is then rapidly converted to formic acid by 
aldehyde dehydrogenase. The formate ion (from the dissociation of formic acid) is 
metabolized to CO2 and H2O via the folate-requiring pathway. In this reaction, a formyl 
group (CHO) is transferred to tetrahydrofolate resulting ultimately in the formation of 
CO2 and H2O (Makar et. al., 1990; Medinsky et. al., 1997). Excess production of formate 
leads to toxicity, which can include optic nerve damage, increased anion gap and 
metabolic acidosis (Medinsky et. al., 1997; Smith & Taylor, 1982). 
Species difference in the metabolism of formate is due to differences in the activities 
of formyltetrahydrofolate synthetase (the enzyme catalyzing the transfer of CHO group 
to tetrahydrofolate), methylenetetrahydrofolate dehydrogenase (which catalyzes the 
removal of H+ from 5, 10-methylenetetrahydrofolate to form 5, 10-
methenyltetrahydrofolate), and the tetrahydrofolate substrate (Black et. al., 1985; Johlin et. 
al., 1987; Johlin et. al., 1989). Species susceptible to methanol/formate poisoning have 
lower hepatic tetrahydrofolate levels and thus slower formate metabolism than resistant 
  121
species such as rats. Pigs have the lowest levels of tetrahydrofolate (3.3 ± 1.1 nmol/g, 
mean ± SEM) compared to rats (11.4 ± 0.8 nmol/g, mean ± SEM) (Tephly et. al., 1992). 
The maximal observable rate of formate metabolism in rats is approximately two-fold 
faster than in monkeys (McMartin, 1977). Thus, adequate tetrahydrofolate levels are 
important for efficient metabolism of formate. 
In this experiment we determine the effect of formate insult on folate utilization 
during folate deficiency in male pigs. We also assess changes in antioxidant and free 
radical levels as in these animals as demonstrated by homocysteine, methylmalonic acid, 
methylglyoxal, S-adenosylmethionine, S-adenosylhomocysteine levels.  
 
6.2 Experimental 
6.2.1 Animals and Husbandry 
Animal husbandry was done as described in 5.2.2. 
 
6.2.2 Formate Formulation and Administration 
Formate formulation and administration was done as described in 5.2.3. 
 
6.2.3 Formate Analysis 
Blood samples (~10 mL) were collected using sterile syringes coated with sodium 
heparin before and at 10, 20, 30, 45, 60, 90, 120, 180, 240 and 480 min post infusion. 
Samples were processed as described in 5.2.3 and analyzed for formate as described 
earlier in Sections 2.2.2 to 2.2.4.   
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6.2.4 Folate utilization 
Folate utilization was assessed by measuring plasma levels of p-
aminobenzoylglutamate (p-ABG) and its acetamido derivative, ap-
acetamidobenzoylglutamate (ap-ABG) as decribed in 3.2.3. 
 
6.2.5 Plasma and Red blood cell (RBC) Folate 
Plasma and RBC folates were determined by an immunoassay technique run on an 
Architect™ system (Abbott Laboratories, IL.) as described in 4.2.6.  
 
6.2.6 Methionine 
Plasma methionine levels were determined using a electrospray ionization tandem 
mass spectrometric (ESI-MS/MS) method. This method involves derivatizing 
methionine to its dibutyl ester before detecting the levels using its mass to charge ratio 
(m/z = 209.1) and that of its product ion after fragmentation (m/z = 107.1). 2H3-
Methionine (Cambridge Isotopes Laboratories, Inc., Andover, MA.; 2.5 µmol/L stock 
solution in methanol) was used as an internal standard. Methionine Standard (Sigma-
Aldrich, St. Louis, MO.) was used to make a standard curve in methanol at 0, 25, 50, 125, 
250, 500 µmol/L levels. ERNDIM samples (www.erndim.unibas.ch) were used as a 
quality control (QC) sample in addition to the in-house QC made by spiking plasma with 
methionine at 25 µmol/L and 125 µmol/L. Each QC was run in duplicate in the middle 
and end of the run. 
Briefly, 50 µL plasma sample was added to 200 µL of methanol, vortex mixed and 
spun down at 2500 rpm for 3 minutes. 25 µL of the supernatant was transferred to a 
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corresponding well in a 96 well plate that contains 180 µL of the internal standard 
solution. After gently mixing for 3 minutes, the solution in the well was evaporated to 
dryness under a stream of nitrogen air at 35°C. Dibutyl ester of methionine was obtained 
by adding 75 µL of butanolic HCl (3M HCl in butanol) to each well, gently mixing for 1 
minutes and incubating for 20 minutes at 80°C. Excess butanolic HCl was evaporated 
under stream of nitrogen as before. Each dry well was then reconstituted with 120 µL of 
acetonitrile-water solution (4:1). This was then gently mixed for 1 minute before injecting 
into an API2000 tandem mass spectrometer (Applied Biosystems-MDS SCIEX, 
Concord, ON.) in positive ion mode. Mass spectrometer parameters were set as follows: 
Curtain gas = 25, Collision gas = 4, Ion Spray Voltage = 5300, Temperature = 300°C, 
Gas 1 = 30, Gas 2 = 40, Focusing Potential = 350, Entrance Potential = 10. 
Quantitation of methionine levels was done using the by plotting the peak area ratios 
of methionine to 2H3-Methionine against the calibration concentrations using Analyst 1.4 
software (Applied Biosystems-MDS SCIEX, Concord, ON.). 
 
6.2.7 Homocysteine (Hcy) 
Plasma homocysteine was determined by an immunoassay technique run on an 
Immulite® 2000 system (DPC Los Angeles, CA) as describe in 4.2.7.  
 
6.2.8 Vitamins B6 & B12 
Plasma vitamin B-6 (PLP) levels were analyzed using HPLC system utilizing the 
method developed by Deitrick and co-workers (Deitrick et. al., 2001b;Deitrick et. al., 
2001) (see section 4.2.8). 
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Plasma vitamin B12 was analyzed using immunoassay technique run on an 
Architect™ system (Abbott Laboratories, IL.) as decribed in 4.2.8.  
 
6.2.9 Methylmalonic Acid (MMA) 
Methylmalonic acid (MMA) was determined using the method developed by 
Schmedes and coworkers (Schmedes & Brandslund, 2006). This is a liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) method and involves a solid 
phase clean up of the plasma samples using a strong anion exchange SPE columns and 
detection by LC-MS/MS.  
Aqueous calibrators were prepared at 0 µM, 0.2 µM, 0.4 µM, 0.75 µM, 1.0 µM, 1.5 
µM, and, 2.0 µM. Plasma samples and calibrators were treated the same by adding 100 µL 
d3-MMA to 500 µL sample/calibrator. This was then diluted with equal volume of 
sodium phosphate buffer (10 mM; pH = 7.4) before applying to a strong anion exchange 
SPE columns (strata-SAX; 100 mg; Phenomenex Corporation, San Diego, CA).  
Selective reaction monitoring (SRM) was done on the mass spectrometer using the 
Sciex Turbo ion spray source in positive ion mode. Resolution in quadrupole 1 (Q1) and 
quadrupole 3 (Q3) chambers were at unit mass. Other source parameters were as 
indicated in Table 3.1. The Multiple SRM mass transitions monitored were 309>162, 
309>180, both for ap-ABG and 267>120 for pABG. The dwell time for all the analytes 
was set at 500 msec. Run time for each LC injection was set at 10 minutes. Data was 
acquired and analyzed using Analyst software 1.4 (Applied Biosystems MDS Sciex). 
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6.2.10 S-adenosylmethionine (SAM) & S-adenosylhomocysteine(SAH) 
S-adenosylmethionine (SAM) & S-adenosylhomocysteine(SAH) levels were 
determined using the method developed by Gellekink and coworkers (Gellekink et. al., 
2005) with some modifications. These modifications involved direction injection of the 
sample into the tandem mass spectrometer rather than using an HPLC column and the 
use of deutrated SAM (2H3-SAM) as an internal standard for both SAM and SAH. 
Precision and recoveries for both SAM and SAH were comparable to what the authors 
obtained. 
The internal standard (1.5 µM 2H3-SAM; 100 µL) was added to 500 µL of the 
calibrators (0 nM, 10 nM, 25 nM, 50 nM, 100 nM) and plasma samples. After mixing well 
the mixture was applied to an SPE column (SPE containing phenylboronic acid; 
BondElut® PBA 100 mg, Varian Inc. Lake Forest, CA.) preconditioned earlier with 5 mL 
of 0.1 M formic acid followed by 5 mL of 20 mM ammonium acetate (pH7.4). The 
column was then washed with 2 mL of 20 mM ammonium acetate (pH7.4) and dried for 
2 min before eluting SAM and SAH with 1 mL 0.1 M formic acid. 15 µL of the eluate 
was injected directly into the triple quadrupole tandem mass spectrometer (API4000, 
Applied Biosystems MDS Sciex) connected to a pump delivering 0.2 mL/L acetic acid in 
water (buffer) and MeOH (solvent) at a rate of 200 µL/min and gradient of 0% - 0.3% 
buffer over a two minute run period.  
Selective reaction monitoring (SRM) was done on the mass spectrometer using the 
Sciex Turbo ion spray source in negative ion mode. Resolution in quadrupole 1 (Q1) and 
quadrupole 3 (Q3) chambers were at unit mass. The Multiple SRM mass transitions 
monitored were 399>250 for SAM, 385>136 for SAH and 402>250 for 2H3-SAM. The 
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dwell time for all the analytes was set at 200 msec. Data was acquired and quantitated 
using Analyst software 1.4 (Applied Biosystems MDS Sciex). 
 
6.2.11 Methylglyoxal 
Analysis of methylglyoxal (MG) was done using the method developed by Randell et. 
al. (Randell et. al., 2005b) with significant author modifications (Randell et. al., 2005a). 
Briefly, 500 µL of plasma was precipitated with 1000 µL trichloroacetic acid (12% v/v). 
After centrifugation, 400 µL of the supernatant was transferred to a clean glass tube to 
which 250 µL of the internal standard (2, 3-hexanedione; 50 ng/mL) was added. This 
mixture was made up to a final volume of 1000 µL using 10 mM disodium hydrogen 
phosphate, Na2HPO4, pH 7.4. 100 µL of 2, 3-diaminonaphthalene, 0.1% v/v in methanol 
(2,3-DAN) was then added to this mixture as a derivatizing agent and incubated at 4ºC 
for at least 24 hrs. The formed methylglyoxal-2, 3-diaminonaphthalene (MG-DAN) and 
2, 3-hexanedione-DAN are extracted from the plasma mixture using 4000 µL (4 mL) of 
ethyl acetate, which is then blown down to dryness under nitrogen and reconstituted in 
200 µL acetonitrile. Calibrators were prepared from pooled plasma by the standard 
addition method and treated as the samples.  
Measurement of methylglyoxal levels was done using liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) that consisted of Agilent 1100 series HPLC system and 
API 4000 tandem mass spectrometer (PE SCIEX, Applied Biosystems). Each run 
consisted of a 5 µL injection into the HPLC system pumping a solvent system made up 
of 0.1% formic acid in water (35%) and acetonitrile (65%) at a flow rate of 300 µL/min 
(3 mL/min) and a C8 column (Symmetry C8; 3.5 um; 2.1x100mm; Waters corporation, 
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WAT058961). Methylglyoxal-2, 3-diaminonaphthalene (MG-DAN) was detected in the 
MS/MS in ESI positive multiple reaction monitoring (MRM) ion mode by monitoring 
the transition 195 >168 while 2, 3-hexanedione-DAN by monitoring the transition 
237>208 in the same ion mode. 
 
6.2.12 Glutathione (GSH) and Glutathione Disulphide (GSSG) 
Reduced (GSH) and oxidized (GSSG) glutathione levels in plasma were determined 
using an LC-MS/MS method developed for the study. Plasma (1 mL) samples and 1 mL 
aqueous calibrators (a mixture of GSH and GSSG; 0 mg/mL, 0.1 mg/L, 0.25 mg/mL, 
0.5 mg/mL and 1.0 mg/mL) were treated similarly and, were diluted in 200 µL 1 N 
NaOH before adding 100 µL of (1 M Iodoacetic acid in 1 N NaOH) to quench and tie 
up the –SH groups of GSH.  This was then mixed thoroughly and incubated at room 
temperature for 30 min. The internal standard (100 µL; 1 mM  2H3-Glutamic acid; CDN 
Isotopes, Pointe-Claire, Qc.) was then added followed by 1 mL acetonitrile (Anachemia, 
Rouses Point, NY) to deproteinate proteins.  
After spinning at 1600g for 5 minutes, the supernatant was placed on a SPE column 
(Strata X-AW 60 mg/3mL; Phenomenex, San Diego, CA) that was preconditioned with 3 
mL 2% formic acid in MeOH (Fisher Scientific, Fair Lawn, NJ) followed by 3 mL 
deionized H2O. Before elution, the column was washed with 3 mL 70% MeOH and dried 
under vacuum for 2 min. Elution of derivatized GSH (molecular weight = 365) and 
GSSG (underivatized) was by application to the column of 1 mL 2% NH4OH (Fisher 
Scientific, Fair Lawn, NJ) in MeOH. The eluate was then dried under nitrogen gas and 
reconstituted in a solution containing 0.1% formic acid in water (90%) and MeOH 
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(10%). The reconstituted solution (15 µL) was injected into triple quadrupole tandem 
mass spectrometer (API2000, Applied Biosystems MDS Sciex) connected to a pump 
delivering 0.1% formic acid in water (90%) as the buffer and MeOH (10%) as solvent at a 
rate of 200 µL/min isocratic over a two minute run period.  
Selective reaction monitoring (SRM) was done on the mass spectrometer using the 
Sciex Turbo ion spray source in negative ion mode. Resolution in quadrupole 1 (Q1) and 
quadrupole 3 (Q3) chambers were at unit mass. Other source parameters were as 
indicated in Table 6.1. The Multiple SRM mass transitions monitored were 364>143, 
364>272, 364>128, for GSH, 611>272, 611>338, 611>306 for GSSG and, 149>105 for 
2H3-Glutamic acid. The dwell time for all the analytes was set at 200 msec. Data was 
acquired and quantitated using Analyst software 1.4 (Applied Biosystems MDS Sciex). 
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Table 6.1: Source parameters for analysis of Glutathione (GSH) and Glutathione 
Disulphide (GSSG) in the tandem mass spectrometer (MS/MS). 
Instrument parameter Value 
Source temperature 500 ºC 
Collision associated dissociation (CAD) gas 2 p.s.i. 
Curtain gas 40 p.s.i. 
Gas source 1 & 2 (GS 1 & GS 2) 40 p.s.i. 
Ion spray voltage -4200 V 
Declustering potential (DP) -15 V 
Electrode potential (EP) -10 eV 
Collision energy (CE) for transition 364>143 -30 eV 
Collision energy (CE) for transition 364>272 -18 eV 
Collision energy (CE) for transition 364>128 -30 eV 
Collision energy (CE) for transition 611>272 -34 eV 
Collision energy (CE) for transition 611>338 -26 eV 
Collision energy (CE) for transition 611>306 -30 eV 
Collision energy (CE) for transition 149>105 -30 eV 
 
6.2.13 Data Analysis 
Mean ± SE values of each analyte were calculated for each group. Two-sample t-test 
was done to compare between the two groups using NCSS 2007 software (NCSS, 
Kaysville, UT.).  
 
6.3 Results  
To induce folate deficiency the designated group (FFD) was fed a folate deficient 
diet. After six weeks folate deficiency was successfully induced as confirmed by the 
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significantly lower (p = 0.007) plasma (26 ± 5 nM, Mean ± SE) folate levels in the FFD 
groupas compared with the FFC group (Table 6.2). To determine whether formate insult 
altered folate utilization during deficiency, pigs were administered formate via a short 
intravenous infusion. At the end of the infusion, plasma formate levels rose from a 
baseline value of 0.16 ± 0.01 mM (mean ± SE) in folate deficiency (FFD) and 0.12 ± 
0.05 mM in folate control (FFC) to a maximum concentration (Cend-inf) of 9.63 ± 0.57 
mM and 10.04 ± 0.71 mM, respectively (Figure 6.2).  
As expected methionine, MMA, vitamin B6 and vitamin B12 levels were not 
statistically different between the two groups (folate-deficient, FFD, and folate-control, 
FFC). In the absence of formate (before formate administration), homocysteine (Hcy) (p 
= 0.019) and methylglyoxal (MG) (p = 0.010) levels were higher in folate deficiency. On 
formate insult, Hcy levels did not rise significantly in folate FFC and FFD groups (p = 
0.382 and p = 0.294, respectively; Figure 6.2). However, MG levels increased in FFD 
group by 43% (from 3.20 ± 0.38 to 4.56 ± 0.40, p = 0.049) after formate administration. 
The increase in MG in FFC group was not significant (8%) (See Figure 6.3).  
The ratio of SAM to SAH was lower in FFD group compared to FFC before 
formate infusion (2.69 ± 0.05 vs 4.23 ± 0.10 in FFC, p = 0.000). A decrease of 45% was 
observed after formate administration in FFC group (from 4.23 ± 0.10 to 2.31 ± 0.46, p 
= 0.007). The decrease was even greater in FFD after formate administration (58%, from 
2.69 ± 0.05 to 1.13 ± 0.07, p = 0.000) (See Figure 6.4).  
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Table 6.2: Summary of various analytes during formate insult in pigs (n = 4/group).  
Parameter FFC FFD p-value 
Conclusio
n 
 Mean ± SE   
Formate Cend-inf (mM) 10.04 ± 0.71 9.63 ± 0.57 0.668 H0 
RBC Folate (nM) 171 ± 35 111 ± 6 0.067 H0 
Plasma Folate (nM) 100 ± 25 26 ± 5 0.007 H1 
Vit B6 (nM) 37 ± 6 49 ± 7 0.137 H0 
Vit B12 (pM) 260 ± 61 311 ± 52 0.450 H0 
Hcy before infusion (µM) 10 ± 3 31 ± 1 0.019 H1 
Hcy at end of infusion (µM) 14 ± 3 38 ± 6 0.000 H1 
MMA (µM) 0.12 ± 0.07 0.28 ± 0.16 0.069 H0 
Methionine (µM) 88 ± 15 93 ± 24 0.845 H0 
Methylglyoxal before infusion (µM) 2.54 ± 0.15 3.20 ± 0.38 0.160 H0 
Methylglyoxal at end of infusion (µM) 2.75 ± 0.25 4.56 ± 0.40 0.010 H1 
SAM before infusion (nM) 289 ± 4 253 ± 4 0.001 H1 
SAM at end of infusion(nM) 191 ± 25 127 ± 22 0.080 H0 
SAH before infusion (nM) 69 ± 2 94 ± 6 0.000 H1 
SAH at end of infusion(nM) 90 ± 18 116 ± 24 0.377 H0 
SAM:SAH before infusion 4.23 ± 0.10 2.69 ± 0.05 0.000 H1 
SAM:SAH at end of infusion 2.31 ± 0.46 1.13 ± 0.07 0.039 H1 
Baseline total folate catabolite (nM) 11.83 ± 2.13 5.33 ± 0.22 0.020 H1 
Catabolite at end of infusion (nM) 15.22 ± 1.60 8.86 ± 0.25 0.006 H1 
Note: FFD= folate-deficient pigs; FFC=folate-control pigs; Formate Cend-inf = 
Formate concentration at end of infusion; H0=no statistical difference between 
means at p=0.05; H1=the means are statistically different (p<0.05); RBC = Red 
blood cell; Vit = vitamin ; MMA = Methylmalonic Acid; SAM = S-
adenosylmethionine (SAM); SAH = S-adenosylhomocysteine(SAH). 
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Figure 6.1: Box plot of mean plasma formate levels before (baseline) and at end of 
a short intravenous infusion (10 min) in male pigs (n=12) of 351 
mg/kg sodium formate (237 mg/kg formate; n=4/group) or saline 
(111-130 mL solution; n=2/group). Ceinf FFD = Formate 
concentration at end of infusion in folate deficient group; Ceinf FFC = 
Formate concentration at end of infusion in folate control group; 
Base_FFD = Formate levels before formate infusion in folate deficient 
group. 
  
Folate catabolite levels were higher in folate replete condition before (p = 0.020) and 
after (p = 0.006) folate insult. Folate utilization as indicated by total folate catabolites 
increased in both groups during formate insult by approximately 1.5 fold (p = 0.014 in 
FFC and p = 0.000 in FFD) (Figures 6.5 and 6.6).  
Glutathione levels (both reduced and oxidized) in pig plasma were undetectable. Our 
method limit of quantitation (LOQ) was 0.1 mg/mL for both GSH and GSSG (326 µM 
for GSH and 163.3 µM for GSSG). Pig plasma glutathione levels are much lower than 
this LOQ (Villanueva et. al., 2006).  
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Figure 6.2: Box plot of mean plasma homocysteine levels in folate control group 
(FFC) and folate deficicent (FFD) before and after a short intravenous 
infusion (10 min) in male pigs (n=4) of 351 mg/kg sodium formate 
(237 mg/kg formate). FFC_Before = Folate Control group before 
infusion of sodium formate; FFC_After = Folate Control group after 
infusion of sodium formate; FFD_Before = Folate Deficient group 
before infusion of sodium formate; FFC_After = Folate Deficient 
group after infusion of sodium formate. 
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Figure 6.3: Box plot of mean plasma Methylglyoxal levels in folate control group 
(FFC) and folate deficicent (FFD) before and after a short intravenous 
infusion (10 min) in male pigs (n=4) of 351 mg/kg sodium formate 
(237 mg/kg formate). FFC_Before = Folate Control group before 
infusion of sodium formate; FFC_After = Folate Control group after 
infusion of sodium formate; FFD_Before = Folate Deficient group 
before infusion of sodium formate; FFC_After = Folate Deficient 
group after infusion of sodium formate. 
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Figure 6.4: Box plot of mean plasma SAM to SAH ratio in folate control group 
(FFC) and folate deficicent (FFD) before and after a short intravenous 
infusion (10 min) in male pigs (n=4) of 351 mg/kg sodium formate 
(237 mg/kg formate). FFC_Before = Folate Control group before 
infusion of sodium formate; FFC_After = Folate Control group after 
infusion of sodium formate; FFD_Before = Folate Deficient group 
before infusion of sodium formate; FFC_After = Folate Deficient 
group after infusion of sodium formate; SAM = S-
Adenosylmethionine: SAH = S-Adenosylhomocysteine. 
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Figure 6.5: Box plot of mean plasma folate catabolites (p-ABG & ap-ABG) levels 
in folate control group (FFD) before and after a short intravenous 
infusion (10 min) in male pigs (n=4) of 351 mg/kg sodium formate 
(237 mg/kg formate). Before_Infusion = Plasma total folate catabolites 
levels before infusion of sodium formate; After_Infusion = Plasma 
total folate catabolites (p-ABG & ap-ABG) levels after infusion of 
sodium formate. 
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Figure 6.6: Box plot of mean plasma folate catabolites (p-ABG & ap-ABG) levels 
in folate deficient group (FFD) before and after a short intravenous 
infusion (10 min) in male pigs (n=4) of 351 mg/kg sodium formate 
(237 mg/kg formate). Before_Infusion = Plasma total folate catabolites 
levels before infusion of sodium formate; After_Infusion = Plasma 
total folate catabolites (p-ABG & ap-ABG) levels after infusion of 
sodium formate. 
 
6.4 Discussion and Conclusion  
Folic acid is an essential vitamin required for a wide range of biochemical pathways 
involving one carbon metabolism. It plays an essential role in cell replication and 
pregnancy because of its requirement in the synthesis of RNA, DNA and amino acids 
(Wagner, 1995). Folate is also required in the metabolism of formate to CO2 and H2O 
during methanol/formic acid intoxication (Makar et. al., 1990; Medinsky et. al., 1997). 
Thus, body folate requirement is directly related to amount of cellular reproduction 
occurring at any given time as well as the state of folate requiring pathways, and is 
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reflected by the plasma levels and urinary excretion of folate catabolites p-
aminobenzoylglutamate (p-ABG) and ap-acetamidobenzoylglutamate (ap-ABG) 
(McPartlin et. al., 1992; McNulty et. al., 1993). In this study, we observed higher baseline 
folate utilization in folate replete condition (11.83 ± 2.13 nM) as compared with folate 
deficiency (5.33 ± 0.22 nM, p = 0.020). This observation is consistent with that made by 
Gregory and coworkers in which rate of folate turnover was increased proportionately to 
folate intake in young women (Gregory, III et. al., 2000).  
Regardless of folate status, folate utilization increases (by at least 29% in FFC) during 
peak formate insult (11.83 ± 2.13 to 15.22 ± 1.60 nM, p = 0.014 in FFC and 5.33 ± 0.22 
to 8.86 ± 0.25 nM, p = 0.000 in FFD; Figures 6.2 and 6.3). Because of the lack of 
information on folate utilization during folate deficiency and formate insult it is not 
possible to compare this observation with others. Nevertheless, we have observed in our 
animals a significant increase in folate utilization during such conditions. This would 
indicate a possible redirection of folate resources from other folate requiring pathways to 
the formate elimination pathway. Such redirection would have profound effects on 
pathways such as DNA synthesis, repair and antioxidant capacity. Impaired cell division 
arising from impaired DNA synthesis may result in megaloblastic changes 
(Wickramasinghe, 1999) and is incompatible with normal fetal growth and development. 
Further evidence of such incompatibility is provided by data that show uracil 
incorporation into DNA instead of thymine with subsequent failure in normal repair to 
remove the misincorporated uracil. This leads ultimately to double strand breakage and 
chromosomal instability, which promotes apoptosis even in the absence of clinical 
symptoms of folate deficiency (Blount et. al., 1997; Koury et. al., 1997). 
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Folate deficiency contributes to the impairment of remethylation pathways, 
particularly that of homocysteine to methionine. We observed elevated Hcy levels in the 
FFD group (38 ± 6 µM vs 14 ± 3 µM in FFC, p = 0.000) and altered ratio of SAM to 
SAH (2.31 ± 0.46 in FFC vs 1.13 ± 0.07 in FFD, p = 0.039) although methionine levels 
were not different between the groups (88 ± 15 µM in FFC vs 93 ± 24 µM in FFD, p = 
0.845). Formate insult also appears to reduce antioxidant capacity regardless of folate 
status as reflected by decreased SAM to SAH ratio. This is worsened by folate deficiency 
state with the decrease being 1.3 times greater in folate deficiency than folate replete. The 
reduced antioxidant capacity is complemented by an increase in methylglyoxal levels, 
despite folate status. The increase is more evident in folate deficiency (43%, p = 0.049) 
compared to folate replete, which was not statistically significant (8% increase, p = 
0.495). 
Homocysteine is a thrombogenic, atherogenic, neurotoxic non-proteinogenic amino 
acid. Elevated plasma homocysteine levels have been implicated in many pathological 
conditions (Refsum, 2001; Refsum et. al., 1998). It mediates endothelial cell dysfunction 
that may contribute to the vascular complications of pregnancy via oxidative stress and 
altered nitric oxide function (Davidge, 1998; Chambers et. al., 1999;Lentz, 1998). 
Increased Hcy has also been linked to congenital abnormalities due to its interaction with 
the N-methyl-D-asparate (NMDA) receptor system, which is involved in neuronal 
development and migration (Andaloro et. al., 1998; Refsum, 2001; Rosenquist et. al., 
1996). S-adenosylmethionine is a compound that is known to activate homocysteine flux 
through the transsulfuration pathway and also is necessary for the utilization of the 
antioxidant glutathione via glutathione S-transferase. Folate deficiency and increased 
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demand for folate would lead to SAM depletion resulting in the reduction in the 
methylation of cytosine in DNA, proteins, phospholipids and neurotransmitters (Mattson 
& Shea, 2003).  
In our study, formate insult and folate deficiency also caused elevations in levels of 
methylglyoxal and Hcy (markers of free radical injury). Methylglyoxal (MG), a reactive 
dicarbonyl compound formed as a by-product of glycolysis and lipid and amino acid 
metabolism (Thornalley, 1993), was increased by about 65% (p = 0.010) in folate 
deficiency (4.56 ± 0.40 µM) during formate insult as compared to the folate replete 
condition (2.75 ± 0.25 µM). Endogenous aldehydes including methylglyoxal are 
compounds of unusually high electrophilic reactivity and undergo nonenzymatic 
conjugation with with free amino (–NH2) and sulfhydryl (–SH) groups of membrane 
proteins, metabolic enzymes and membrane ion channels, thereby, inhibiting their 
function (Schauenstein & Esterbauer, 1979). The autoxidation of methylglyoxal, its ability 
to generate more reactive oxygen species (ROS), and its toxicity, mediated via increased 
apoptosis and mutagenicity in the presence of superoxide anion and hydrogen peroxide, 
are well documented (Yamaguchi & Nakagawa, 1983; Kalapos, 1999; Shangari et. al., 
2004; Shangari et. al., 2003). Under normal physiological conditions methylglyoxal levels 
are kept low in the body mainly by its catabolism via a glutathione dependent glyoxalase 
system or its conjugation to cysteine, the product of which is subsequently excreted in 
bile and urine (Schauenstein et. al., 1977). The increased methylglyoxal levels seen in 
folate deficiency is probably due to the increased demand for glutathione to handle the 
increased in free radicals generated as a result of formate (Dikalova et. al., 2001). As a 
result less is available to handle methylglyoxal.  
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In conclusion, we have demonstrated that formate insult increases folate utilization 
despite folate deficiency; increases free radical markers; and reduces antioxidant capacity 
as reflected by SAM to SAH ratio. These observations could have disastrous 
consequences on vital folate-dependent metabolic pathways, e.g., DNA synthesis and 
repair and antioxidant capacity of the body, during folate deficiency. The clinical 
implications of such findings require further investigation, particularly the effect of 
alcohol/methanol intoxication in pregnant women. 
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CHAPTER 7 
Discussion and Concusions 
7.1 Background 
Fetal Alcohol Spectrum Disorder (FASD) is a preventable, devastating life-long 
developmental condition affecting children of women who abuse alcohol during 
pregnancy. The costs and consequences of FASD, both personally and financially, are 
tremendous to the affected individuals’ families and the society at large. It is estimated that 
the annual average costs of caring for FASD affected children, once diagonized is US $ 
2,342 per capita more than the annual average cost of care for children in who do not 
have FASD (US $500 per year) (Klug & Burd, 2003). The annual savings in health care 
costs alone, after 10 years of prevention, for one case of FASD would be US $23,420 
dollars, US $ 128,810 dollars in 10 years and, US $491,820 dollars after 20 years. With an 
estimated annual birth rate of 1200 children diagonized with FASD, the estimated 
incremental annual cost of treating this disorder is US $74.6 million (Abel & Sokol, 1991). 
Approximately three-quarters of these costs are associated with mental health care.  
Most of the studies linking prenatal alcohol consumption to FASD have identified 
ethanol as the culprit (Abel, 1999b; Chaudhuri, 2000b; Chaudhuri, 2000a; Jones & Smith, 
1973; Jones et. al., 1973), although the jury is still out on whether “alcohol” rather than 
“its abuse” is responsible for FASD (Abel, 1999b; Abel, 1999a). Despite the presence of 
methanol in alcoholic beverages (Caldwell, 1986; Gilg et. al., 1987; Majchrowicz & 
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Mendelson, 1971; Paine & Dayan, 2001; Roine et. al., 1989), no research to date has 
addressed the link that might exist between formate, a toxic metabolite of methanol, and 
FASD. This study attempts to address part of this question. It addresses, first, the 
question of the relationship between formate and folate levels in drinking women (see 
section 7.2), secondly, the kinetics of formate elimination in folate deficiency (see section 
7.3); thirdly, changes in markers of free radicals and antioxidant capacity during formate 
insult in folate deficiency state (see section 7.3). 
Although this study does not provide a link between the elevated formate, folate 
deficiency and occurrence of FASD/alcohol-related birth defects, it does provide 
evidence, identifying formate (probably as a result of increased alcohol intake) in folate 
deficiency state as a candidate alternative causative agent of FASD, and forms the basis 
for further research in that area. 
In order to execute the study protocol novel methods had to be developed to 
determine formate levels (see chapter 2) and folate utilization (see chapter 3) in the 
experimental subjects. Together with other established methods, formate’s presence, 
kinetics and role in altered antioxidant status was investigated. 
7.2 Human Experiments 
Methanol is present in alcoholic beverages (see chapter 1). To investigate whether 
alcohol consumption translated to elevated methanol and formate levels and, any 
correlation this might have on folate levels, intoxicated human female volunteers were 
recruited from the emergency room of a university hospital while two groups of sober 
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human females were recruited from a detox centre (non-pregnant females) and a prenatal 
clinic (pregnant females) (Chapter 4). Subjects were recruited to represent alcohol 
intoxication state (intoxicated females), malnutrition state (as represented in recovering 
alcoholics in the detox program) and, pregnancy state (represented by the prenatal clinic 
recruits).  
In this study, we observed elevated methanol levels during intoxication compared to 
sober individuals (mean ± SE, 0.13 ± 0.01mM in intoxicated vs 0.04 ± 0.00 in sober, 
respectively; p = 0.003). The elevated methanol is due to the alcohol intake that was absent 
in the detox subjects. For a pregnant mother involved in binge drinking (consumption of 4 
or more drinks in about 2 hours) such an elevation, in methanol levels, would prove 
disastarous for the fetus. Elevated methanol would, therefore, lead to higher formate levels. 
However, this was not the observational case where mean formate levels were not different 
between the intoxicated and detox groups (0.10 ± 0.00 mM in the intoxicated group vs 0.10 
± 0.01 mM in the detox group, p = 1.000). Methanol has to be metabolized to 
formaldehyde by alcohol dehydrogenase and then, by aldehyde dehydrogenase, to formate. 
During this metabolism, methanol levels fall as formate levels increase. In the presence of 
ethanol, alcohol dehydrogenase preferentially metabolizes ethanol. In our intoxicated 
subjects, blood sampling might have been done before significant methanol metabolism 
occurred, explaining the low formate levels. A definite negative (inverse), albeit weak, 
relationship exits between plasma formate and folate levels (correlation = -0.4989). 
However, this relationship could not be observed between whole blood formate and RBC 
folate in the intoxicated and detox females. 
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There might be some nutritional benefit from consumption of grain and fruit based 
alcoholic drinks (Kellner & Cejka, 1999; Mayer Jr. et. al., 2001; Walker & Baxter, 2000)(see 
Table 4.4). This would explain the higher levels of folate and B-vitamins seen in the 
intoxicated group compared to the detox group. Higher folate, vitamin B6 and vitamin B12 
have a Hcy lowering effect (Bleich et. al., 2000; Lakshmi et. al., 1910; Mayer Jr. et. al., 2001; 
Pietrzik & Bronstrup, 157; Walker & Baxter, 2000), thus, could explain the lower levels 
seen in the intoxicated group. However, this could be a short-term benefit and is reversed 
in chronic alcoholism (Barak et. al., 1987; Halsted et. al., 2002b; Halsted et. al., 2002d; 
Halsted et. al., 2002c; Larroque et. al., 1992; Mayer Jr. et. al., 2001) as observed in the detox 
group. Therefore, adequate nutritional status, especially folate, and abstinence from alcohol 
would be beneficial in reducing methanol and, subsequently, formate accumulation.  
7.3 Pig Experiments 
This study also assessed the kinetics of formate during formate insult (as would be 
seen during binge drinking) in folate deficiency state in folate deficient pigs (Chapter 5). In 
this study formate accumulated due to formate administration regardless of folate status as 
observed in the mean end of infusion formate levels in folate deficient and folate replete 
pigs (mean ± SE, 9.63 ± 0.57 mM in folate deficiency vs 10.04 ± 0.71 in folate replete, p = 
0.668). However, formate exposure is lower in folate replete condition (AUC = 30.08 ± 
2.58 g min L-1 vs 72.37 ± 8.29 g min L-1 in folate deficiency, p = 0.003) due to the faster 
systemic clearance (0.27 ± 0.02 L min-1 vs 0.12 ± 0.01 L min-1 in folate deficiency, p = 
0.001) resulting in shorter half-life (45 ± 6 min vs 113 ± 17 min in folate deficiency, p = 
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0.009) and mean residency time (65 ± 8 min vs 163 ± 24 min in folate deficiency, p = 
0.008). It is evident that adequate folate status is important in preventing prolonged 
formate exposure. 
Elevated formate coupled with folate deficiency enhanced free radical accumulation 
and compromised antioxidant status as observed in the increased MG levels (by 43%, p = 
0.049) and reduced SAM to SAH ratio (by 58%, p = 0.000). Folate deficiency alone also 
appears to increase Hcy levels (by 210%, p = 0.019) and MG (by 26%). It also reduces 
SAM to SAH ratio by 57%, p = 0.000. A reduction in this ratio indicates alteration in the 
trans-sulphuration pathway and risk on oxidative stress. 
Although the ratio of plasma GSH to GSSG is a good indicator of antioxidant 
capacity, we were unable to measure this despite setting up a method for this. This was due 
to the very low levels of glutathione in pigs and the sensitivity of our method (LOQ = 326 
µM for GSH and 163.3 µM for GSSG). Despite this, we were able to show changes in 
antioxidant capacity using changes in methylglyoxal, homysteine, S-adenosylmethionine 
and S-adenosylhomocysteinelevels. However, we have been able to show, for the first time, 
real time changes in folate utilization during formate insult in these animals. This could 
form the basis for future studies in folate and formate kinetics in humans. 
7.4 Conclusions 
This study aimed at addressing some fundamental questions (as described in the 
hypothesis section 1.6) regarding formate presence in the body after alcohol consumption 
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and the role it plays in antioxidant capacity during folate deficiency. The conclusions of this 
study are: 
1. methanol levels increase during alcohol consumption and might lead to increased 
formate levels. 
2. plasma formate levels correlate negatively with plasma folate levels in the body.  
3.  formate kinetics are altered during formate insult in folate deficiency state leading 
to reduced clearance, longer half-life and mean residency time and, consequently, 
increased exposure. 
4. folate utilization is increased during formate insult independent of folate status.  
5. formate insult during folate deficiency reduces antioxidant capacity in the body. 
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